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Open acceAbstract Introduction: Cancer incidence and mortality estimates for 25 cancers are presented
for the 40 countries in the four United Nations-deﬁned areas of Europe and for the European
Union (EU-27) for 2012.
Methods: We used statistical models to estimate national incidence and mortality rates in 2012
from recently-published data, predicting incidence and mortality rates for the year 2012 from
recent trends, wherever possible. The estimated rates in 2012 were applied to the correspond-
ing population estimates to obtain the estimated numbers of new cancer cases and deaths in
Europe in 2012.
Results: There were an estimated 3.45 million new cases of cancer (excluding non-melanoma
skin cancer) and 1.75 million deaths from cancer in Europe in 2012. The most common cancer
sites were cancers of the female breast (464,000 cases), followed by colorectal (447,000), pros-
tate (417,000) and lung (410,000). These four cancers represent half of the overall burden of
cancer in Europe. The most common causes of death from cancer were cancers of the lung
(353,000 deaths), colorectal (215,000), breast (131,000) and stomach (107,000). In the Euro-
pean Union, the estimated numbers of new cases of cancer were approximately 1.4 million27
on of Cancer Information, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372
rlay).
ss under CC BY-NC-ND license.
J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403 1375in males and 1.2 million in females, and around 707,000 men and 555,000 women died from
cancer in the same year.
Conclusion: These up-to-date estimates of the cancer burden in Europe alongside the descrip-
tion of the varying distribution of common cancers at both the regional and country level pro-
vide a basis for establishing priorities to cancer control actions in Europe. The important role
of cancer registries in disease surveillance and in planning and evaluating national cancer
plans is becoming increasingly recognised, but needs to be further advocated. The estimates
and software tools for further analysis (EUCAN 2012) are available online as part of the
European Cancer Observatory (ECO) (http://eco.iarc.fr).
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Up-to-date cancer incidence and mortality data in
Europe are a key resource in both planning and assessing
the impact of cancer control programmes at the country
and regional level. Europe carries a signiﬁcant load of the
global burden, with one quarter of the global burden of
cancer observed in Europe in 2008 despite a total popu-
lation that comprises one-ninth of the world’s popula-
tion.1,2 The International Agency for Research on
Cancer (IARC), through its programmes of collabora-
tion with population-based cancer registries in Europe,
members of the European Network of Cancer Registries
(ENCR, http://www.encr.com.fr/) has provided esti-
mates of cancer burden at the European and European
Union (EU) member state level over the last 25 years.3–8
In this paper, we provide estimates of the incidence of,
and the mortality from cancer for 25 sites in 40 European
countries in 2012, using the most recently available data.
The reported estimates are based on the latest incidence
data provided by theENCRmember registries, theWorld
Health Organisation (WHO) mortality database9 and
UN population estimates.2 The results are also presented
for four areas as deﬁned by the UN (Eastern, Northern,
Southern and Western Europe),2 and the European
Union 27 Member States (EU-27). The complete set of
estimates is available through the European Cancer
Observatory (ECO) website (http://eco.iarc.fr).10.
2. Data sources and methods
Cancer incidence and mortality for 2012 by sex and
16 age groups (0–4, 5–9,. . ., 70–74, 75 and over) are esti-
mated for each of the 39 European countries deﬁned by
the United Nations2 and Cyprus. Results are presented
for the following cancer sites as deﬁned by the 10th edi-
tion of the International Classiﬁcation of Diseases
(ICD-10)11: lip, oral cavity and pharynx (ICD-10 C00–
14), oesophagus (C15), stomach (C16), colorectal
(including anus C18–21), liver (C22), gallbladder
(C23–24), pancreas (C25), larynx (C32), lung (including
trachea, C33–34), melanoma of skin (C43), female
breast (C50), cervix uteri (C53), corpus uteri (C54),
ovary (C56), prostate (C61), kidney (including renal pel-
vis and ureter, C64–66), bladder (C67), brain and centralnervous system (C70–72), thyroid (C73), Hodgkin lym-
phoma (C81), non-Hodgkin lymphoma (C82–85, C96),
multiple myeloma (C88 + C90), leukaemia (C91–95)
and all cancers combined, excluding non-melanoma skin
cancer (C00–96, except C44). This last category was cal-
culated by summing the estimated counts for each indi-
vidual cancer site, and the corresponding estimate of the
residual category “other and unspeciﬁed cancers”. No
attempt was made to estimate incidence and mortality
from non-melanoma skin cancer given the non-system-
atic registration of these cases in most cancer registries.
2.1. Development of the estimates
The methods used to estimate country-speciﬁc inci-
dence and mortality rates for 2012 are based on previous
work,8 and involve projections of the most recent national
rates available prior to 2012. For countries with ﬁfteen or
more years of recent incidence or mortality data available,
corresponding rates for 2012 were predicted using the
NORDPRED program based on age-period-cohort
modelling12 separately for each cancer site and sex. When
the available information was for less than 15 years, or
when data up to 2010 were available, a programme devel-
oped at IARC (DEPPRED) based on the simple time-lin-
ear prediction models of Dyba and Hakulinen13 was used
to make the short-term predictions. To reduce the pros-
pect of erroneous predictions as a result of inherently large
random variation due to small numbers (rare cancers,
small populations), cancer-, sex-speciﬁc prediction models
were ﬁtted only when at least 50 cancer cases or cancer
deaths (all ages) were recorded per year for DEPPRED,
andwhen at least 100 cancer cases or deaths (all ages) were
recorded per 5-year period for NORDPRED. For the sex
and cancer combinations where these criteria were not
satisﬁed, the rates for 2012 were derived from the annual
average rates recorded in the most recent 5-year period
available. For countries where no historical national
incidence or mortality data existed, the most recent dis-
ease rates available were used as proxy for 2012. For
France, we used the published estimates of national inci-
dence rates for 2011.14 Since no data were available for
Montenegro, incidence and mortality rates were estimated
as the simple average of the rates (age-, sex- and site-
speciﬁc) of those of Bosnia Herzegovina and Serbia.
Table 1
Data availability and method of estimation.
Country Mortality Incidence
Albania 1995–2004a > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from cancer registries of Bulgaria and central
Serbia)
Austria 1990–2009 > 2012
(NORDPRED)
National incidence 1990–2009 > 2012 (NORDPRED)
Belarus 2008–2009 = 2012b National incidence 1978–2007 > 2012 (NORDPRED)
Belgium 2005–2006 = 2012 National incidence 2008–2009 = 2012
Bosnia
Herzegovina
Bosnia Herzegovina 2009 and Republika Srpska 2004–2005 = 2012
Bulgaria 1990–2009 > 2012
(NORDPRED)
National incidence 1994–2008 > 2012 (NORDPRED)
Croatia 1990–2009 > 2012
(NORDPRED)
National incidence 1988–2007 > 2012 (NORDPRED)
Cyprus 2008–2009 = 2012 National incidence 2006–2007 = 2012
Czech Republic 1990–2009 > 2012
(NORDPRED)
National incidence 1989–2008 > 2012 (NORDPRED)
Denmark 1987–2006 > 2012
(NORDPRED)
National incidence 1990–2009 > 2012 (NORDPRED)
Estonia 1990–2009 > 2012
(NORDPRED)
National incidence 1988–2007 > 2012 (NORDPRED)
Finland 1990–2009 > 2012
(NORDPRED)
National incidence 1990–2009 > 2012 (NORDPRED)
France 2001–2009 > 2012
(DEPPRED)
National incidence 2011 (estimated) = 2012
Germany 1990–2009 > 2012
(NORDPRED)
Local incidence from 9 pooled German cancer registries 2000–2008 > 2012 (DEPPRED) and
applied to 2012 population
Greece 1990–2009 > 2012
(NORDPRED)
Estimated mortality! incidence (I:M ratio from cancer registries of Bulgaria, Cyprus and
central Serbia)
Hungary 1990–2009 > 2012
(NORDPRED)
Estimated mortality! incidence (I:M ratio from cancer registries of Austria, Croatia,
Slovakia, Slovenia and central Serbia)
Iceland 1990–2009 > 2012
(NORDPRED)
National incidence 1990–2009 > 2012 (NORDPRED)
Ireland 1990–2009 > 2012
(NORDPRED)
National incidence 1994–2007 > 2012 (NORDPRED)
Italy 2000–2009 > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from 17 Italian cancer registries).
Latvia 2001–2010 > 2012
(DEPPRED)
National incidence 1988–2007 > 2012 (NORDPRED)
Lithuania 2001–2010 > 2012
(DEPPRED)
National incidence 1988–2007 > 2012 (NORDPRED)
Luxembourg 1990–2009 > 2012
(NORDPRED)
Estimated mortality! incidence (I:M ratio from 11 French and 9 German cancer registries)
FYR Macedonia 2004–2010a>2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from cancer registries of Bulgaria and central
Serbia)
Malta 1990–2009 > 2012
(NORDPRED)
National incidence 2000–2009 > 2012 (DEPPRED)
Moldova 2001–2010 > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from Ukrainian cancer registry)
Montenegro Simple mean of Bosnia and Serbia rates
Norway 1990–2009 > 2012
(NORDPRED)
National incidence 1990–2009 > 2012 (NORDPRED)
Poland 2001–2010 > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from 3 Polish cancer registries).
Portugal 2000–2009 > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from 2 Portuguese and 12 Spanish cancer
registries)
Romania 2001–2010 > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from cancer registries of Bulgaria, Slovakia and
Romania, Cluj county)
Russian
Federation
2000–2009 > 2012
(DEPPRED)
National incidence 1994–2008 > 2012 (NORDPRED)
Serbia 2001–2010 > 2012
(DEPPRED)
Estimated mortality! incidence (I:M ratio from cancer registries of Croatia, Slovenia and
central Serbia)
Slovakia 1990–2009 > 2012
(NORDPRED)
National incidence 1988–2007 > 2012 (NORDPRED)
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Table 1 (continued)
Country Mortality Incidence
Slovenia 1990–2009 > 2012
(NORDPRED)
National incidence 1989–2008 > 2012 (NORDPRED)
Spain 1990–2009 > 2012
(NORDPRED)
Estimated mortality! incidence (I:M ratio from 12 Spanish cancer registries)
Sweden 1990–2009 > 2012
(NORDPRED)
National incidence 1990–2009 > 2012 (NORDPRED)
Switzerland 2000–2007c>2012
(DEPPRED)
Local incidence from 7 pooled Swiss cancer registries 1988–2007 > 2012 (NORDPRED) and
applied to 2012 population
The Netherlands 1990–2009 > 2012
(NORDPRED)
National incidence 1989–2008 > 2012 (NORDPRED)
Ukraine 2009 = 2012c National incidence 2009 = 2012
United Kingdom 1990–2009 > 2012
(NORDPRED)
National incidence 1993–2007 > 2012 (NORDPRED)
“>” projected to.
“!” converted to incidence.
“=” applied to.
a Corrected for under-reporting. Missing sites: mean average of the estimated mortality rates for Bulgaria and Serbia.
b Main category (ICD special list) only. Other category partitioned using mortality data from Ukrainian cancer registry.
c Main category (ICD-10 special list) only. Other category partitioned using mortality data from local (Switzerland) or national (Ukraine) cancer
registries.
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incidence and mortality rates were smoothed using a
loess function by country, sex and cancer site. The
derived age-, sex- and site-speciﬁc rates were age-stand-
ardised (ASRs per 100,000 person-years) using the
European standard population.15 The number of cancer
cases and deaths in 2012 was computed for each country
and cancer site by multiplying the predicted 2012 age-
and sex-speciﬁc incidence and mortality rates by the cor-
responding 2012 population estimates from the UN
Population Division (the 2010 revision).2 The data
sources available for the estimation of the 2012 rates,
and the methods applied in the incidence and mortality
estimations are summarised in Table 1.
2.2. Mortality
For 38 European countries, cancer mortality data
from 1990 to 2010 and corresponding population ﬁgures
were available through the WHO mortality database.9
For Bosnia Herzegovina, the data were extracted from
the federal cancer registry.16 For Albania and Macedo-
nia, vital registration is known to be incomplete during
the period under study9; the source data were therefore
corrected using the estimated percentage of under-
reporting estimated by the WHO. The changes in the
use of ICD in 2000 in France and in 1995 in Switzerland
resulted in discontinuity in trends17,18 and thus the
French and Swiss mortality estimates are derived using
short-term predictions based on the period from 2000
using DEPPRED (Table 1). For Italy and Portugal,
mortality data were missing for one or more calendar
years in the period 2004–2006, and the nearest available
data (generally that of the previous or subsequent year)
were replicated to replace the missing values.There are large variations in the accuracy of death
certiﬁcates related to cancer of the uterus, with many
deaths recorded as “uterus cancer, not otherwise speci-
ﬁed” (ICD-10 C55). By default, the cancer deaths coded
as “uterus unspeciﬁed category” were reallocated to
either cervix uteri or corpus uteri cancer according to
the observed age-speciﬁc proportions of each when the
all age proportion of uterine cancer deaths coded to
the unspeciﬁed category was considered to be low
(<25% of the total).19 For the other countries (Austria,
Belgium, France, Germany, Ireland, Italy, Portugal,
Slovenia, Sweden and Switzerland) we estimated the
all-age proportions of deaths from cervix and corpus
uteri cancers using the recorded incidence in local or
national cancer registries around 2000 and the corre-
sponding 5-year relative survival probabilities extracted
from the EUROCARE 4 study.20 The total number of
cancer deaths from uterine cancers (ICD-10 C53–55)
estimated in 2012 were then partitioned into cervix
and corpus uteri cancers using the proportions obtained
from the survival analysis, and then further stratiﬁed by
age using age-speciﬁc death counts of the two sites
extracted from the WHO mortality database. Finally,
for the countries with large proportion (more than
25%) of unspeciﬁed uterine cancers and no incidence
and survival data (Albania, FYR Macedonia, Greece
and Luxembourg) we used pooled incidence and sur-
vival data from Belgium and France to reallocate the
uterine cancer deaths in Luxembourg and a pool from
Malta, Slovenia and Portugal was used for the other
listed countries. In addition, for Belarus and the
Ukraine, the deaths from “corpus uteri and uterus, not
otherwise speciﬁed” (ICD-10 C54–55) were ﬁrst parti-
tioned into two components using proportions from
the Ukrainian National Cancer Registry mortality data
Table 2
Cancer- and sex-speciﬁc comparisons of estimated cancer cases in Finland 2012.
Site Finnish cancer
registry
International Agency for Research on
Cancer (IARC)
Male
Prostate 5093 5366
Lung, trachea 1700 1682
Colorectum 1580 1551
Bladdera 710 869
Non-Hodgkin lymphoma 672 641
Melanoma of the skin 667 670
Pancreas 579 555
Kidney 485 477
Brain, central nervous systemb 409 242
Stomach 373 368
Leukaemia 359 374
Liver 381 407
Oesophagus 190 194
Multiple myeloma 177 199
Testis 149 144
Larynx 107 104
All sites but non-melanoma skin
cancers
15,009 15,204
Female
Breast 4707 4477
Colorectum 1371 1345
Corpus uteri 873 860
Lung, trachea 797 812
Brain, central nervous systemb 603 188
Non-Hodgkin lymphoma 580 567
Melanoma of the skin 562 538
Pancreas 594 596
Ovary 447 457
Kidney 405 405
Thyroid gland 303 291
Stomach 272 273
Leukaemia 258 279
Bladdera 197 224
Liver 215 213
Cervix uteri 140 143
Gallbladder 144 151
Multiple myeloma 143 159
All sites but non-melanoma skin
cancers
13,859 13,224
Finnish Cancer Registry. Cancer in Finland 2008 and 2009. Cancer Society of Finland Publication No.
84, Helsinki 2011.
a IARC estimates include non-malignant tumours.
b Finnish estimates include benign tumours.
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speciﬁed” was then distributed into the cervix and cor-
pus uteri categories using the age-speciﬁc proportions
from the same source.
For Belarus, Switzerland and Ukraine, national mor-
tality data for several cancer sites selected for this study
were not available. Thus for cancers of the gallbladder,
testis, kidney, thyroid as well as Hodgkin lymphoma,
the mortality rates from the Ukrainian National Cancer
Registry21 were applied to the national population esti-
mates in Belarus and the Ukraine in 2012, whereas for
Switzerland, the rates from the regional Swiss mortality
statistics 2004–200822 were applied to the corresponding
population data.As noted above, projections of national mortality
rates were carried out only when a minimum threshold
in the number of deaths was recorded per year for a
given sex and cancer combination. Otherwise, the mor-
tality rates from the most recent 5-year period were
applied to the 2012 population.
2.3. Incidence
Recent regional and national (up to 2009) incidence
data were extracted from EUREG, part of the ECO
website10 as well as from the NORDCAN database of
the Association of Nordic Cancer Registries.23 National
and regional incidence data for other countries were
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Fig. 1. Prediction of incidence rates for female breast (a) and prostate (b) cancers in Croatia (1993–2007) and predicted incidence (2008–2022) using
NORDPRED (circle points). The predicted incidence rate for female breast cancer for the period 2008–2017 (mid period 2012, circle point) was
used, while for prostate cancer, only the ﬁrst predicted period 2008–2012 (mid period 2010, square point) was considered.
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series24,25 and national incidence data for 2009 in Bosnia
Herzegovina and Ukraine were extracted from pub-
lished reports.16,21 The methods to estimate the national
sex- and age-speciﬁc incidence rates in 2012 areTable 3
Estimated numbers of new cancer cases and deaths from cancer (thousands
Europe in 2012.
Incidence
Both sexes Male Fe
Cases ASR
(E)
Cases ASR
(E)
Ca
Oral cavity and pharynx 99.6 11.0 73.9 18.2 2
Oesophagus 45.9 4.7 35.1 8.4 1
Stomach 139.6 13.7 84.2 19.5 5
Colon and rectum 446.8 43.5 241.6 55.7 20
Liver 63.4 6.2 42.8 10.0 2
Gallbladder 29.7 2.7 11.9 2.7 1
Pancreas 103.8 10.1 51.9 12.1 5
Larynx 39.9 4.4 36 8.8
Lung 409.9 41.9 290.7 68.3 11
Melanoma of skin 100.3 11.1 47.2 11.4 5
Breast 46
Cervix uteri 5
Corpus uteri 9
Ovary 6
Prostate 416.7 96.0
Testis 21.5 5.8
Kidney 115.2 12.1 71.7 17.2 4
Bladder 151.2 14.4 118.3 26.9 3
Brain, nervous system 57.1 6.6 30.7 7.8 2
Thyroid 52.9 6.3 12.3 3.1 4
Hodgkin lymphoma 17.6 2.3 9.3 2.5
Non-Hodgkin lymphoma 93.4 9.8 49.5 11.9 4
Multiple myeloma 38.9 3.8 20.5 4.7 1
Leukaemia 82.3 8.8 46.4 11.3 3
All sites but non-melanoma skin
cancers
3439.6 355.7 1829.1 429.9 161summarised in Table 1 and fall into one of the following
categories, listed in order of priority:
1. Estimates based on national and local incidence data
(27 countries, Table 1).), age-standardised rates (ASRs) (per 100,000) by sex and cancer site in
Mortality
male Both sexes Male Female
ses ASR
(E)
Deaths ASR
(E)
Deaths ASR
(E)
Deaths ASR
(E)
5.8 4.9 43.7 4.7 34.2 8.4 9.4 1.6
0.8 1.8 39.5 3.9 30.3 7.1 9.2 1.4
5.4 9.3 107.3 10.3 63.6 14.6 43.7 7.0
5.2 34.7 214.7 19.5 113.2 25.2 101.5 15.4
0.6 3.3 62.1 5.9 39.9 9.1 22.2 3.4
7.9 2.8 20.9 1.9 7.9 1.8 13.0 2.0
1.8 8.3 104.5 9.9 52.6 12.2 51.9 8.1
3.9 0.8 19.8 2.1 18.1 4.3 1.7 0.3
9.2 21.6 353.5 35.2 254.4 59.1 99.0 17.2
3.1 11.0 22.2 2.3 12.1 2.8 10.1 1.8
3.8 94.2 131.2 23.1
8.3 13.4 24.4 4.9
8.9 19.3 23.7 3.9
5.5 13.1 42.7 7.6
92.2 19.3
1.6 0.4
3.4 8.1 49.0 4.7 31.3 7.2 17.7 2.8
2.9 5.3 52.4 4.5 39.5 8.5 12.9 1.8
6.4 5.6 45.0 4.9 24.6 6.0 20.4 4.0
0.7 9.3 6.3 0.6 2.1 0.5 4.3 0.7
8.3 2.1 4.6 0.5 2.6 0.6 2.0 0.4
3.9 8.0 37.9 3.5 20.3 4.6 17.5 2.7
8.4 3.1 24.3 2.2 12.2 2.7 12.1 1.8
5.9 6.9 53.8 5.1 29.5 6.7 24.3 3.9
0.5 306.3 1754.6 168.0 975.9 222.6 778.6 128.8
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Fig. 2. Distribution of the expected cases and deaths for the 5 most common cancers in Europe 2012 in males (a) and females (b). For each sex, the
area of the segment of the pie chart reﬂects the proportion of the total number of cases or deaths.
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bers of recorded cases were available, incidence rates
were projected to 2012 using either the NORDPRED
or DEPPRED methods. This method for predicting
incidence in 2012 was used in 20 countries, and validated
for Finland by comparing our estimates to thosecomputed by the Finnish Cancer Registry for the same
year.26 The close agreement between the two sets of esti-
mates is shown in Table 2.
1B.Whenhistorical regional incidence data covering at
least 30% of a country and suﬃcient numbers of recorded
cases were available (Germany and Switzerland), local
Table 4
Most common leading types of cancer in terms of new cases (i) and deaths (m) in each of the European countries in 2012.
i m i m i m i m i m i m
Europe Prostate Lung Breast Breast Lung Colorectum Colorectum Colorectum Colorectum Prostate Lung Lung
EU-27 Prostate Lung Breast Breast Lung Colorectum Colorectum Lung Colorectum Prostate Lung Colorectum
Albania Lung Lung Breast Lung Stomach Stomach Lung Breast Prostate Prostate Stomach Stomach
Austria Prostate Lung Breast Breast Lung Colorectum Colorectum Lung Colorectum Prostate Lung Colorectum
Belarus Lung Lung Breast Breast Prostate Stomach Colorectum Colorectum Colorectum Colorectum Corpus uteri Stomach
Belgium Prostate Lung Breast Breast Lung Prostate Colorectum Colorectum Colorectum Colorectum Lung Lung
Bosnia Herzegovina Lung Lung Breast Breast Prostate Colorectum Colorectum Lung Colorectum Prostate Lung Colorectum
Bulgaria Lung Lung Breast Breast Colorectum Colorectum Colorectum Colorectum Prostate Prostate Corpus uteri Lung
Croatia Lung Lung Breast Breast Prostate Colorectum Colorectum Colorectum Colorectum Prostate Lung Lung
Cyprus Prostate Lung Breast Breast Colorectum Prostate Colorectum Colorectum Lung Colorectum Thyroid Lung
Czech Republic Prostate Lung Breast Breast Colorectum Colorectum Colorectum Lung Lung Prostate Lung Colorectum
Denmark Prostate Lung Breast Lung Colorectum Prostate Colorectum Breast Lung Colorectum Lung Colorectum
Estonia Prostate Lung Breast Colorectum Lung Prostate Colorectum Breast Colorectum Colorectum Corpus uteri Lung
Finland Prostate Lung Breast Breast Lung Prostate Colorectum Lung Colorectum Colorectum Corpus uteri Colorectum
France Prostate Lung Breast Breast Lung Colorectum Colorectum Lung Colorectum Prostate Lung Colorectum
Germany Prostate Lung Breast Breast Colorectum Colorectum Colorectum Lung Lung Prostate Lung Colorectum
Greece Lung Lung Breast Breast Prostate Prostate Colorectum Colorectum Bladder Colorectum Lung Lung
Hungary Lung Lung Breast Lung Colorectum Colorectum Colorectum Colorectum Prostate Oral cavity, pharynx Lung Breast
Iceland Prostate Lung Breast Lung Lung Prostate Lung Breast Colorectum Colorectum Colorectum Colorectum
Ireland Prostate Lung Breast Lung Colorectum Colorectum Colorectum Breast Lung Prostate Lung Colorectum
Italy Prostate Lung Breast Breast Lung Colorectum Colorectum Colorectum Colorectum Prostate Lung Lung
Latvia Prostate Lung Breast Breast Lung Prostate Colorectum Colorectum Colorectum Colorectum Corpus uteri Ovary
Lithuania Prostate Lung Breast Breast Lung Prostate Colorectum Colorectum Colorectum Colorectum Cervix uteri Ovary
Luxembourg Prostate Lung Breast Lung Colorectum Colorectum Colorectum Breast Lung Prostate Corpus uteri Colorectum
FYR Macedonia Lung Lung Breast Breast Prostate Stomach Corpus uteri Colorectum Colorectum Colorectum Colorectum Lung
Malta Prostate Lung Breast Breast Colorectum Colorectum Colorectum Colorectum Lung Prostate Corpus uteri Ovary
Moldova Lung Lung Breast Breast Colorectum Colorectum Colorectum Colorectum Prostate Stomach Cervix uteri Cervix uteri
Montenegro Lung Lung Breast Breast Colorectum Colorectum Colorectum Lung Prostate Prostate Lung Colorectum
Norway Prostate Lung Breast Lung Colorectum Prostate Colorectum Colorectum Lung Colorectum Lung Breast
Poland Lung Lung Breast Lung Colorectum Colorectum Colorectum Breast Prostate Prostate Lung Colorectum
Portugal Prostate Lung Breast Breast Colorectum Colorectum Colorectum Colorectum Lung Prostate Corpus uteri Stomach
Romania Lung Lung Breast Breast Colorectum Colorectum Colorectum Colorectum Prostate Stomach Cervix uteri Lung
Russian Federation Lung Lung Breast Breast Prostate Stomach Colorectum Colorectum Colorectum Colorectum Corpus uteri Stomach
Serbia Lung Lung Breast Breast Colorectum Colorectum Colorectum Lung Prostate Prostate Lung Colorectum
Slovakia Colorectum Lung Breast Breast Prostate Colorectum Colorectum Colorectum Lung Oral cavity, pharynx Corpus uteri Lung
Slovenia Prostate Lung Breast Breast Lung Colorectum Colorectum Colorectum Colorectum Prostate Lung Lung
Spain Prostate Lung Breast Breast Lung Colorectum Colorectum Colorectum Colorectum Prostate Corpus uteri Lung
Sweden Prostate Prostate Breast Lung Colorectum Lung Colorectum Breast Lung Colorectum Lung Colorectum
Switzerland Prostate Lung Breast Lung Colorectum Prostate Colorectum Breast Lung Colorectum Lung Colorectum
The Netherlands Prostate Lung Breast Lung Colorectum Colorectum Colorectum Breast Lung Prostate Lung Colorectum
Ukraine Lung Lung Breast Breast Colorectum Colorectum Colorectum Colorectum Stomach Stomach Corpus uteri Stomach
United Kingdom Prostate Lung Breast Lung Colorectum Prostate Lung Breast Lung Colorectum Colorectum Colorectum
First Second Third
FemalesMales Females Males Females Males
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NORDPRED or DEPPRED and applied to the 2012
national population. In the absence of such data, the local
incidence rates from the most recent available 5-year per-
iod were applied to the 2012 national population.
For female breast and prostate cancers, the projec-
tion method 1A or 1B could potentially yield unreason-
ably high values if, for example mammographic
screening programmes or PSA testing commenced,
respectively, in the calendar period serving as the basis
for the estimates. For both cancers, a careful examina-
tion of the observed and predicted trends in rates was
performed. When the predicted incidence rate for 2012
yielded what was considered by the authors an unrealis-
tically high value, the incidence rate from the most
recent 5-year period was applied to the 2012 population
(Fig. 1). Such an adjustment was applied in Austria and
Denmark for female breast cancer and in Austria, Bela-
rus, Croatia, Czech Republic, Ireland, Lithuania, Slova-
kia and the United Kingdom for prostate cancer.1C. When national incidence rates were available
only for a short period of time, the incidence rates for
the most recent period available were applied to the
2012 population (ﬁve countries, including national esti-
mates for France14).
1. Estimates based on local incidence data and national
mortality data (12 countries, Table 1).
National incidence (IN) was estimated by applying a
set of sex-, site- and age-speciﬁc incidence to corre-
sponding mortality ratios (IR/MR) obtained from the
aggregation of local registries’ incidence data, to the cor-
responding national mortality estimate for 2012 (MN):
IN ¼MN  IR=MR ð1Þ
Before aggregation, each registry dataset was weighted
according to the square root of its population to take
into account the relative size of the population covered.
In practice, the IR/MR ratios were obtained from a
Table 5
Estimated numbers of new cancer cases and deaths from cancer (thousands), age-standardised rates (ASRs) (per 100,000) by sex and cancer site in
the European Union (EU-27) in 2012.
Incidence Mortality
Both sexes Male Female Both sexes Male Female
Cases ASR
(E)
Cases ASR
(E)
Cases ASR
(E)
Deaths ASR
(E)
Deaths ASR
(E)
Deaths ASR
(E)
Oral cavity and pharynx 73.0 11.6 53.4 18.3 19.6 5.5 28.2 4.3 21.5 7.2 6.7 1.7
Oesophagus 34.5 5.0 26.0 8.4 8.5 2.0 29.6 4.1 22.2 7.0 7.4 1.7
Stomach 80.6 10.7 49.9 15.2 30.7 7.1 57.7 7.3 34.9 10.4 22.8 4.9
Colon and rectum 342.1 46.3 191.6 59.0 150.5 36.1 150.0 18.4 81.8 23.8 68.2 14.2
Liver 51.3 7.0 35.6 11.1 15.8 3.6 48.0 6.2 31.6 9.6 16.4 3.5
Gallbladder 23.5 3.0 9.6 2.8 13.9 3.1 16.0 2.0 6.1 1.8 9.8 2.1
Pancreas 78.7 10.5 39.1 12.2 39.6 9.0 77.9 10.1 38.9 11.9 39.1 8.5
Larynx 28.0 4.4 24.9 8.3 3.1 0.9 12.0 1.8 10.8 3.4 1.3 0.3
Lung 309.6 44.1 211.4 66.3 98.2 26.1 264.8 36.5 183.4 56.4 81.4 20.6
Melanoma of skin 82.1 13.0 39.6 13.2 42.5 13.1 15.7 2.2 8.8 2.8 6.9 1.7
Breast 364.4 108.8 90.6 22.4
Cervix uteri 33.4 11.3 13.0 3.7
Corpus uteri 64.3 17.9 14.7 3.3
Ovary 44.1 12.6 29.8 7.4
Prostate 359.9 110.8 71.0 18.9
Testis 18.0 7.2 0.9 0.3
Kidney 84.4 12.4 53.8 17.4 30.6 8.0 34.7 4.5 22.3 6.7 12.4 2.7
Bladder 123.1 16.3 96.4 29.1 26.7 6.1 40.3 4.7 29.9 8.4 10.3 2.0
Brain, nervous system 42.5 6.9 23.1 8.1 19.4 5.9 32.6 4.9 18.0 6.0 14.5 4.0
Thyroid 36.9 6.5 9.6 3.5 27.3 9.3 3.6 0.4 1.4 0.4 2.2 0.5
Hodgkin lymphoma 12.3 2.3 6.7 2.6 5.6 2.1 2.7 0.4 1.5 0.5 1.1 0.3
Non-Hodgkin lymphoma 78.8 11.6 42.2 13.8 36.5 9.6 30.4 3.8 16.4 4.9 14.0 3.0
Multiple myeloma 33.4 4.5 17.9 5.5 15.5 3.7 20.3 2.5 10.4 3.0 9.9 2.1
Leukaemia 62.2 9.2 35.9 11.8 26.3 7.1 41.1 5.2 22.9 6.8 18.2 4.0
All sites but non-melanoma skin
cancers
2634.6 382.0 1434.3 452.9 1200.3 330.1 1262.4 164.6 707.5 211.8 554.9 128.4
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age. Depending on the accuracy and availability of local
data, one of two variants of the method was used, as
speciﬁed below:
2A. Country-speciﬁc models were ﬁtted for three
countries (Italy, Poland and Spain) with several local
cancer registries in operation: the IR/MR ratios were
obtained from the most recent country-speciﬁc data
(generally a 5-year period centred on year 2005), under
the assumption that the IR/MR ratios will be reasonably
constant in recent years. This assumption is likely to be
violated for female breast and prostate cancers, particu-
larly following the introduction of screening pro-
grammes, which may have resulted in marked
ﬂuctuation in the ratios of recorded cases to deaths.
For these two cancer sites we used the most recent inci-
dence rates from the cancer registries used in the model
(generally the year 2007) as a proxy for the 2012 national
incidence rate. To achieve a greater stability in the inci-
dence to mortality ratios where the country-speciﬁc local
data were sparse, additional incidence and mortality data
from local cancer registries in neighbouring countries
within the same area were included prior to modelling.
2B. Regional models were ﬁtted when no incidence
data were available or when they were considered tobe lacking suﬃcient quality (nine countries). The IR/
MR ratios were obtained by the aggregation of cancer
registry data in neighbouring countries. Speciﬁcally for
Luxembourg, we applied the age-speciﬁc incidence rates
(2007–2009) recorded by the national pathological regis-
try27 to the national 2012 population where zero cancer
deaths were recorded for a particular combination of sex
and cancer type. We applied the same redistribution
procedure of the number of cancer deaths coded as
“uterus unspeciﬁed” described above to the local mor-
tality used in the models in methods 2A and 2B.
3. Results
Table 3 and Fig. 2 summarise the estimated numbers
of new cancer cases and cancer deaths in Europe in 2012
(in thousands), by type of cancer. There were just over
3.4 million new cases of cancer (excluding non-mela-
noma skin cancers) in Europe in 2012, 53% (1.8 million)
occurring in men and 47% (1.6 million) in women. The
most common cancer sites were breast cancer (464,000
cases, 13.5% of all cancer cases), followed by colorectal
cancer (447,000, 13.0%), prostate cancer (417,000,
12.1%) and lung cancer (410,000, 11.9%). These four
cancers represented half (50.5%) of the estimated overall
Table 6a
Estimated age-standardised rates (ASRs) (European standard) of cancer incidence by sex, cancer site and country, 2012.
Oral cavity and
pharynx
Oesophagus Stomach Colon and
rectum
Liver Gallbladder Pancreas Larynx Lung Melanoma Breast Cervix
C00–14 C15 C16 C18–21 C22 C23–24 C25 C32 C33–34 C43 C50 C53
M F M F M F M F M F M F M F M F M F M F F F
Europe 18.2 4.9 8.3 1.8 19.5 9.3 55.7 34.6 10.0 3.3 2.7 2.8 12.1 8.3 8.8 0.8 68.3 21.6 11.4 11.0 94.2 13.4
EU-27 18.3 5.5 8.4 2.0 15.2 7.1 59.0 36.1 11.1 3.6 2.9 3.1 12.2 9.0 8.3 0.9 66.3 26.1 13.2 13.1 108.8 11.3
Central and Eastern Europe 20.6 3.8 7.9 1.1 29.7 12.9 51.1 31.5 6.9 2.9 2.4 2.8 12.8 7.4 10.9 0.6 77.3 14.8 6.1 6.0 63.4 19.2
Belarus 24.9 2.3 9.6 0.6 42.1 17.2 45.6 29.9 4.8 1.8 1.9 1.9 10.4 5.1 12.3 0.3 81.7 8.7 4.8 5.9 60.5 15.8
Bulgaria 15.1 3.7 4.1 0.6 21.4 10.4 58.7 36.4 9.2 3.5 2.7 2.8 15.1 8.8 14.0 0.7 73.1 12.4 5.2 4.0 76.3 28.5
Czech Republic 18.0 6.1 8.0 1.4 15.5 7.8 81.1 40.5 9.5 3.9 5.3 7.3 17.8 12.0 7.9 0.7 75.0 25.9 19.1 15.3 95.5 16.3
Hungary 39.8 9.5 9.6 1.3 20.3 9.7 86.7 44.6 8.0 2.2 4.2 4.5 16.7 11.1 16.6 1.9 109.3 46.5 10.6 8.1 72.3 20.5
Moldova 22.8 3.0 4.9 0.3 26.4 9.2 52.0 32.9 17.7 7.8 0.7 1.2 14.0 9.7 15.5 0.6 61.3 11.9 3.4 3.0 52.9 24.1
Poland 19.0 4.6 5.7 1.2 19.7 7.4 55.5 28.9 5.4 3.0 3.1 5.6 12.7 8.2 11.7 1.3 89.6 31.1 6.0 5.3 69.9 15.3
Romania 29.6 3.3 5.9 0.7 23.7 8.5 50.3 29.2 13.1 4.5 2.2 2.3 14.9 8.7 14.1 0.5 83.3 15.8 4.7 4.4 66.2 34.9
Russian Federation 17.9 3.5 9.2 1.4 35.8 15.6 44.6 31.5 6.3 2.8 2.0 2.0 11.7 6.8 9.5 0.4 74.3 9.8 5.0 5.7 60.7 17.7
Slovakia 30.3 4.8 9.0 1.2 21.0 9.8 92.2 43.6 10.0 3.7 5.3 6.8 17.1 11.7 9.6 0.7 70.0 20.5 14.9 12.1 78.1 19.4
Ukraine 22.0 3.0 7.6 0.7 32.1 12.9 43.6 28.1 4.3 1.9 1.7 1.8 12.0 5.9 11.5 0.4 66.9 8.7 5.0 5.6 54.0 19.2
Northern Europe 13.4 5.8 12.1 4.2 11.2 5.5 55.1 37.8 6.7 2.8 1.2 1.7 10.9 8.9 4.8 0.8 52.3 34.9 19.1 19.4 120.8 9.9
Denmark 18.0 8.3 8.3 3.5 12.3 4.5 69.2 53.4 6.4 2.0 3.1 3.2 14.0 11.7 6.1 1.3 62.5 54.9 22.0 26.6 142.8 12.0
Estonia 15.1 4.2 6.5 0.9 28.7 14.9 53.1 33.8 4.9 2.4 2.5 1.9 14.7 7.2 7.9 0.4 70.7 13.5 8.9 10.7 69.0 23.3
Finland 9.9 5.6 5.4 1.8 10.2 5.9 42.5 29.2 11.1 4.2 2.8 2.9 15.1 11.8 2.9 0.3 45.4 17.9 19.9 14.5 121.0 4.9
Iceland 8.9 5.9 10.1 2.4 9.6 5.6 44.5 41.7 3.4 2.0 1.8 2.0 7.7 7.7 2.2 0.0 47.6 43.0 12.3 17.8 130.7 8.8
Ireland 11.9 4.9 12.5 5.1 13.4 6.7 65.1 41.3 6.7 3.3 2.5 3.5 11.3 9.2 6.7 1.3 54.9 40.4 17.7 18.6 122.4 15.1
Latvia 14.8 2.6 10.1 1.5 33.7 12.6 45.5 30.0 8.4 2.7 1.6 1.8 15.4 9.3 11.9 0.6 83.9 11.7 7.6 7.9 69.8 20.7
Lithuania 19.1 3.3 10.7 1.2 33.5 11.8 47.4 28.1 6.9 2.1 2.7 2.0 15.4 7.9 11.2 0.4 80.8 10.4 7.4 6.8 65.2 31.6
Norway 10.8 6.8 5.8 1.7 8.7 5.7 65.0 53.8 4.1 2.0 2.5 2.4 12.1 10.0 3.4 0.6 52.3 38.1 26.6 24.8 98.4 11.3
Sweden 9.5 5.7 5.2 1.6 7.4 4.1 48.9 39.4 5.0 2.3 2.0 3.0 7.4 6.5 2.4 0.5 28.8 27.5 24.1 24.1 108.2 8.6
United Kingdom 13.9 6.0 15.0 5.4 10.0 4.8 55.6 36.7 6.8 2.9 0.5 1.1 10.4 8.8 4.8 0.9 53.3 38.5 18.6 19.6 129.2 7.9
Southern Europe 13.6 4.0 4.6 0.8 17.6 8.8 58.7 35.2 13.9 4.4 3.3 3.1 11.3 8.1 10.2 0.8 69.0 18.3 10.1 10.0 96.8 10.0
Albania 9.3 5.3 2.6 1.1 36.2 22.2 12.7 11.2 7.7 4.4 0.5 0.5 9.3 4.7 6.5 2.7 54.0 24.5 1.5 1.1 69.4 6.2
Bosnia Herzegovina 9.4 3.7 2.5 0.9 14.9 8.5 30.0 19.0 8.3 5.4 3.1 3.5 7.0 4.1 11.2 1.5 65.1 15.5 2.7 2.3 49.1 16.2
Croatia 20.2 5.1 7.7 1.0 21.8 9.5 66.7 36.7 12.2 3.2 4.5 5.2 13.2 8.0 13.3 1.1 85.4 22.3 12.0 11.9 83.0 12.1
Cyprus 4.2 1.3 2.2 0.8 11.4 4.8 41.6 33.2 6.4 2.8 2.1 2.4 7.4 5.4 4.1 0.5 38.1 10.7 4.4 4.6 104.3 5.2
Greece 5.5 1.8 2.3 0.3 11.1 5.4 24.9 17.2 8.3 2.9 2.6 1.8 10.6 6.9 6.5 0.4 74.7 13.2 3.8 2.6 58.6 6.2
Italy 9.8 4.0 3.1 0.8 16.5 8.8 61.2 39.9 16.3 5.6 3.5 3.5 11.2 9.1 9.0 0.7 58.8 19.2 13.5 13.6 118.0 7.7
FYR Macedonia 7.0 2.4 1.7 0.3 34.8 15.4 41.1 29.9 8.5 3.9 1.5 2.0 17.0 6.5 12.9 0.9 101.6 19.2 7.2 6.0 101.4 15.6
Malta 14.9 5.3 5.5 1.5 17.0 8.1 60.1 37.6 5.1 1.7 3.4 1.7 15.6 10.2 7.9 1.4 58.0 11.0 6.6 8.4 116.2 4.6
Montenegro 14.4 5.3 4.1 1.1 17.0 9.5 49.8 28.9 9.9 5.2 3.1 3.9 10.3 7.4 12.7 1.4 85.5 25.9 7.3 4.7 75.9 23.0
Portugal 27.5 4.6 8.5 0.7 26.7 12.8 61.4 33.9 11.9 2.5 4.4 1.9 9.7 5.5 13.0 0.4 49.1 11.7 7.5 8.8 85.6 10.8
Serbia 18.8 5.2 5.7 1.2 17.1 8.1 62.1 33.2 9.6 4.0 2.8 3.8 12.3 8.6 14.1 1.4 99.2 32.9 11.2 7.4 92.3 28.3
Slovenia 20.6 5.2 5.4 1.0 23.3 9.6 74.5 40.1 12.5 3.1 5.6 6.7 14.2 11.7 7.2 0.7 78.9 24.8 21.2 20.5 88.4 11.8
Spain 16.8 4.2 6.4 1.0 16.4 7.5 65.6 35.3 14.2 3.7 3.0 2.5 11.5 7.6 11.0 0.9 76.8 15.7 8.3 9.0 84.9 9.1
(continued on next page)
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Table 6a (continued)
Oral cavity and
pharynx
Oesophagus Stomach Colon and
rectum
Liver Gallbladder Pancreas Larynx Lung Melanoma Breast Cervix
C00–14 C15 C16 C18–21 C22 C23–24 C25 C32 C33–34 C43 C50 C53
M F M F M F M F M F M F M F M F M F M F F F
Western Europe 21.5 6.8 9.8 2.3 13.4 6.3 58.6 36.9 11.8 3.3 3.1 3.0 12.3 9.5 6.8 1.0 64.2 28.1 15.4 15.8 126.8 8.7
Austria 16.5 5.5 7.2 1.1 13.9 7.4 51.3 29.3 12.1 4.2 2.6 2.8 14.5 10.6 5.0 0.8 54.2 27.8 13.1 12.4 90.7 7.0
Belgium 21.9 7.0 10.8 2.9 12.2 5.7 67.5 43.4 6.7 2.4 2.3 2.1 9.6 7.2 9.4 1.5 83.2 27.6 11.9 18.2 147.5 10.2
France 23.1 7.6 8.7 2.5 10.5 4.2 53.8 36.9 16.6 3.6 2.7 2.3 11.7 8.7 7.8 1.3 74.5 27.9 13.1 13.1 136.6 8.0
Germany 23.1 6.4 9.9 2.0 16.2 8.0 59.7 34.8 10.6 3.5 3.4 3.7 13.2 10.5 6.5 0.7 57.3 25.4 15.3 14.8 122.0 9.7
Luxembourg 16.4 6.5 9.0 2.5 14.7 7.2 62.5 33.6 15.9 5.5 0.8 0.9 11.2 8.5 5.2 0.9 59.7 26.9 15.0 13.9 118.2 7.1
The Netherlands 12.6 7.0 14.9 4.2 11.6 5.8 71.6 50.5 3.3 1.2 3.2 2.3 10.8 8.0 5.8 1.1 66.1 44.5 22.5 26.5 131.3 8.0
Switzerland 18.0 6.6 9.0 2.8 7.5 5.1 54.2 35.0 12.7 3.0 2.8 2.9 10.7 9.3 4.5 0.6 52.0 29.7 26.8 25.4 111.3 4.2
Corpus Ovary Prostate Testis Kidney Bladder Brain Thyroid Hodgkin NHL Multiple
myeloma
Leukaemia All sites
C54 C56 C61 C62 C64–66 C67 C70–72 C73 C81 C82–
85,C96
C88 + C90 C91–95 C00–96/C44
F F M M M F M F M F M F M F M F M F M F M F
Europe 19.3 13.1 96.0 5.8 17.2 8.1 26.9 5.3 7.8 5.6 3.1 9.3 2.5 2.1 11.9 8.0 4.7 3.1 11.3 6.9 429.9 306.3
EU-27 17.9 12.6 110.8 7.2 17.4 8.0 29.1 6.1 8.1 5.9 3.5 9.3 2.6 2.1 13.8 9.6 5.5 3.7 11.8 7.1 452.9 330.1
Central and Eastern Europe 21.4 14.8 48.3 3.2 17.0 8.2 22.4 4.0 7.0 5.3 2.2 9.0 2.1 1.9 6.3 4.7 2.3 1.9 9.7 6.1 371.3 259.1
Belarus 23.2 14.0 53.5 2.7 21.2 10.4 21.2 2.8 5.4 4.8 4.1 16.3 2.5 2.7 6.0 3.7 2.7 2.5 13.5 8.2 391.0 250.6
Bulgaria 24.3 17.9 37.1 6.0 13.5 5.7 28.0 6.5 10.5 7.7 1.1 5.7 2.2 1.9 6.6 4.9 2.7 2.3 8.3 5.6 367.0 290.5
Czech Republic 25.4 15.1 110.3 8.7 34.9 15.0 28.9 8.3 7.3 6.1 3.7 13.8 2.6 1.8 10.6 8.5 3.7 2.5 9.7 6.1 503.4 356.8
Hungary 10.5 14.1 56.6 11.1 19.4 6.7 34.3 10.5 5.8 4.3 2.9 8.8 1.6 1.4 8.8 7.0 2.2 1.6 11.2 7.0 500.3 319.4
Moldova 17.1 9.7 30.4 2.1 8.6 4.2 17.6 3.4 5.7 4.0 2.2 8.3 2.0 1.1 6.5 5.0 1.2 1.7 6.0 4.1 323.2 229.8
Poland 23.4 18.1 55.3 4.6 15.4 8.1 30.3 6.4 10.7 9.4 1.8 6.2 2.2 1.5 6.2 5.6 3.1 2.9 9.8 5.4 389.7 283.6
Romania 11.6 13.6 37.9 3.0 11.2 4.9 27.4 4.1 8.3 6.0 1.2 5.3 1.2 1.6 7.2 5.5 2.9 2.2 9.3 5.7 381.6 253.7
Russian Federation 22.0 14.5 46.6 1.8 17.2 8.7 18.0 2.8 5.7 4.3 2.2 9.9 2.0 1.9 5.7 4.3 1.9 1.6 9.5 6.4 352.1 249.6
Slovakia 26.8 15.4 78.3 9.4 24.7 11.9 28.2 5.9 10.3 7.5 2.4 7.2 2.0 2.3 10.1 9.0 4.8 4.4 14.8 8.1 488.9 327.8
Ukraine 22.4 13.6 31.1 2.6 14.8 6.8 18.9 2.5 6.2 4.5 2.2 8.2 2.5 2.4 4.9 3.3 1.6 1.4 9.0 5.4 325.6 228.2
Northern Europe 20.0 14.9 127.7 7.4 15.7 8.1 19.3 5.6 8.5 6.1 2.1 6.7 2.8 2.0 16.1 11.4 6.2 4.0 12.1 7.4 434.0 363.3
Denmark 19.2 14.3 138.4 12.5 14.0 6.6 35.2 10.7 8.8 6.3 2.3 4.8 2.5 2.2 16.2 11.5 4.5 3.5 10.1 6.5 515.0 454.4
Estonia 20.2 15.8 145.4 3.5 24.9 10.6 21.8 4.3 7.8 4.4 2.2 7.3 2.4 1.6 9.9 5.0 5.2 3.0 12.9 8.2 471.4 275.1
Finland 20.1 11.5 145.2 5.8 13.7 9.1 23.4 4.3 7.7 5.2 3.1 9.5 2.7 2.4 18.6 13.1 5.4 3.3 11.3 7.3 423.3 323.8
Iceland 16.8 8.5 159.9 7.1 17.8 8.4 28.0 8.9 7.8 7.2 3.5 14.4 1.1 1.8 15.8 9.9 6.5 3.0 11.4 5.3 442.2 381.5
Ireland 15.6 15.6 168.7 9.1 15.7 8.7 20.5 7.5 9.0 5.9 1.9 4.7 2.9 2.5 17.2 12.9 7.0 5.2 17.0 8.2 499.6 382.4
Latvia 23.2 18.9 127.2 4.8 23.3 10.0 26.5 5.9 11.2 9.2 3.1 8.8 2.1 1.7 7.9 5.4 3.1 2.4 11.4 7.4 472.7 280.5
Lithuania 24.5 16.2 93.8 2.0 29.4 11.8 23.7 6.8 8.3 8.0 4.7 24.2 2.1 1.9 10.2 7.2 4.9 4.0 13.3 9.3 454.1 302.6
Norway 24.0 13.3 193.2 12.7 17.9 8.5 33.5 9.8 11.0 9.1 3.0 7.2 3.1 1.9 17.4 12.5 8.8 5.5 12.4 7.7 535.7 383.8
Sweden 19.7 10.3 175.2 7.2 11.2 6.4 25.7 7.1 10.8 13.1 1.8 5.4 2.0 1.5 13.8 10.2 5.3 3.6 10.4 7.8 427.8 340.3
United Kingdom 19.7 16.0 111.1 7.1 15.7 8.0 14.8 4.5 8.0 4.8 1.9 5.7 3.0 2.1 16.8 12.0 6.5 4.1 12.4 7.3 415.8 370.5
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o
W Cburden of cancer in Europe in 2012. The most common
primary sites in men were prostate (22.8% of the total),
lung (291,000, 15.9%), colorectal (242,000, 13.2%) and
bladder (118,000, 6.5%). In women, breast cancer was
by far the most frequently diagnosed neoplasm (28.8%
of the total), followed by colorectal (205,000, 12.7%),
lung (119,000, 7.4%) and corpus uteri (99,000, 6.1%)
cancers. The estimated total number of cancer deaths
in Europe in 2012 was 1.75 million, of which 56%
(976,000) were in men and 44% (779,000) in women.
Lung cancer, with an estimated 353,000 deaths (one ﬁfth
of the total) was the most frequent cause of death from
cancer in Europe in 2012, followed by colorectal cancer
(almost 215,000 deaths, 12.2%), breast cancer (131,000,
7.5%) and stomach cancer (107,000, 6.1%). Lung cancer
continued to be the most common cause of death from
cancer in men (254,000, 26.1%) followed by colorectal
(113,000, 11.6%) and prostate (92,000, 9.5%) cancers.
Breast cancer was the leading cause of death in women
(131,000, 16.8%), followed by colorectal (102,000,
13.0%) and lung (almost 100,000 deaths, 12.7%) cancers.
Table 4 shows the numbers of new cases and deaths
for three most common leading types of cancer in each
of the European countries in 2012.
Table 5 shows the estimated numbers of cases and
deaths by site of cancer and sex (in thousands) for the
27 countries of the European Union (EU-27). The
EU-27 accounted for an estimated 2.6 million new cases
(76% of the European total) and 1.26 million deaths
(72%) in 2012. The most common forms of cancers were
breast cancer (364,000 cases, 13.8% of all cancer cases),
followed by prostate cancer (360,000, 13.7%), colorectal
cancer (342,000, 13.0%) and lung cancer (310,000,
11.8%). These four cancers represented 52% of the over-
all burden of cancer in the EU-27 in 2012. Lung cancer,
with an estimated 265,000 deaths (21.0% of total) was by
far the most common cause of death from cancer, fol-
lowed by colorectal cancer (150,000 deaths, 11.9%),
breast cancer (91,000, 7.2%) and pancreatic cancer
(78,000, 6.2%).
Tables 6a and 6b show the estimates of incidence and
mortality rates by sex and site, for all 40 countries.
Tables 7a and 7b portray the estimated numbers of cases
and deaths for the same categories. A brief description
of the patterns for the four most common cancers in
Europe follows.3.1. Overall patterns
After adjusting for diﬀering population age struc-
tures, overall incidence rates in both sexes were highest
in Northern and Western European countries, in men
in France (550 per 100,000) and in women in Denmark
(454) (Figs. 3a, b and 4a). For both male and female, the
lowest all-cancer incidence rates were to be found in the
Balkan Peninsula with rates almost half in Bosnia Herz-
Table 6b
Estimated age-standardised rates (ASRs) (European standard) of cancer mortality by sex, cancer site and country, 2012.
Oral cavity and
pharynx
Oesophagus Stomach Colon and
rectum
Liver Gallbladder Pancreas Larynx Lung Melanoma Breast Cervix
C00–14 C15 C16 C18–21 C22 C23–24 C25 C32 C33–34 C43 C50 C53
M F M F M F M F M F M F M F M F M F M F F F
Europe 8.4 1.6 7.1 1.4 14.6 7.0 25.2 15.4 9.1 3.4 1.8 2.0 12.2 8.1 4.3 0.3 59.1 17.2 2.8 1.8 23.1 4.9
European Union (EU)-27 7.2 1.7 7.0 1.7 10.4 4.9 23.8 14.2 9.6 3.5 1.8 2.1 11.9 8.5 3.4 0.3 56.4 20.6 2.8 1.7 22.4 3.7
Central and Eastern Europe 12.8 1.7 7.1 0.9 24.8 10.4 31.0 17.7 7.8 3.3 1.9 2.2 13.0 7.3 7.0 0.3 69.3 12.0 2.7 1.9 23.2 8.0
Belarus 16.0 1.0 8.7 0.4 36.0 13.7 26.4 15.4 4.5 1.4 1.1 0.9 11.3 4.8 8.7 0.1 72.8 5.4 2.5 2.1 19.5 6.0
Bulgaria 9.8 2.7 3.5 0.4 17.9 8.0 32.3 18.2 11.6 5.2 1.5 1.6 13.1 7.1 9.4 0.4 67.6 11.3 2.4 1.4 24.1 8.8
Czech Republic 9.3 2.1 6.3 1.0 10.6 5.2 35.4 15.8 7.1 3.0 4.2 5.6 15.5 11.2 3.5 0.3 59.3 19.1 3.2 1.7 19.2 4.4
Hungary 23.1 3.7 8.6 1.1 16.1 7.5 46.3 22.5 7.5 2.4 3.4 3.7 16.2 10.7 8.6 0.8 96.4 37.7 3.4 1.9 23.4 6.9
Moldova 15.3 1.4 4.1 0.3 21.7 7.5 32.4 18.4 20.0 8.6 0.7 1.1 13.3 8.2 10.1 0.4 52.3 9.1 1.9 1.1 25.7 10.3
Poland 9.6 1.8 5.5 1.0 16.8 6.0 31.8 15.9 5.5 3.1 2.5 4.5 12.3 8.0 6.5 0.7 82.9 25.3 3.5 2.3 19.7 7.4
Romania 17.9 1.6 5.4 0.7 19.2 6.9 27.5 14.7 16.0 6.2 1.7 1.6 13.5 7.6 8.6 0.4 71.4 13.6 1.7 1.2 21.6 14.2
Russian Federation 11.6 1.6 8.4 1.1 30.6 12.9 30.6 19.2 7.9 3.3 1.7 1.6 13.2 7.5 6.6 0.2 68.7 8.3 2.7 1.9 24.2 7.8
Slovakia 19.8 2.3 8.2 1.0 14.6 6.9 42.0 18.8 8.4 3.5 4.1 5.0 14.7 11.5 5.9 0.3 59.1 13.0 3.9 2.4 19.1 6.9
Ukraine 14.6 1.3 6.2 0.4 26.4 10.3 27.8 15.7 4.5 2.1 1.3 1.5 11.2 4.9 7.6 0.2 56.5 6.6 2.5 1.8 25.1 7.8
Northern Europe 4.5 1.6 10.9 3.6 7.4 3.7 21.3 14.4 6.1 2.8 0.9 1.3 10.8 8.6 1.9 0.3 45.4 28.7 3.7 2.2 23.7 2.9
Denmark 7.2 2.7 9.8 2.9 6.0 3.0 26.9 20.3 6.4 1.6 1.4 1.6 12.6 9.2 2.5 0.5 53.9 42.3 3.6 2.5 28.0 2.6
Estonia 7.9 1.3 7.3 0.4 18.3 8.9 27.5 12.5 6.0 2.5 1.7 1.9 14.2 8.5 4.3 0.2 59.7 10.5 4.1 2.4 15.1 6.1
Finland 3.2 1.4 4.4 1.5 7.4 4.3 16.2 10.8 7.9 3.5 2.0 2.5 13.6 10.7 0.9 0.1 39.6 14.2 4.1 1.6 19.7 1.4
Iceland 1.8 0.7 7.1 1.4 4.9 4.4 14.9 9.6 4.1 2.4 1.1 0.4 8.7 6.7 0.0 0.0 41.6 35.0 4.0 3.3 20.7 0.7
Ireland 4.3 1.5 10.6 4.2 8.8 4.4 25.4 14.1 5.8 3.7 0.6 1.0 11.0 8.4 2.7 0.3 45.9 27.6 3.8 2.1 27.4 4.2
Latvia 10.6 1.6 9.8 1.0 24.0 9.8 27.8 15.9 6.5 2.6 1.5 1.5 15.6 8.3 7.6 0.2 73.4 7.9 3.1 2.7 24.5 8.2
Lithuania 15.5 1.7 10.4 1.0 24.8 9.2 30.8 15.9 6.7 2.4 1.5 1.5 14.8 7.2 9.6 0.3 69.6 6.8 3.5 1.9 23.4 9.8
Norway 2.6 1.2 4.9 1.3 5.1 3.9 23.2 19.4 3.3 2.0 0.6 0.4 11.1 9.4 1.2 0.1 41.0 27.9 7.0 3.5 18.3 3.1
Sweden 3.1 1.5 4.7 1.4 5.7 2.8 19.6 15.4 5.7 2.7 2.5 3.5 11.0 10.5 0.7 0.1 26.4 24.1 5.1 3.1 19.5 2.6
United Kingdom 4.0 1.6 13.2 4.7 6.6 3.1 20.6 13.7 6.1 3.0 0.6 0.8 10.0 8.2 1.6 0.3 46.7 32.4 3.2 2.1 24.8 2.4
Southern Europe 5.7 1.4 4.1 0.7 12.9 6.2 24.5 13.8 11.5 4.1 2.3 2.3 11.1 7.7 4.3 0.3 59.1 14.6 2.3 1.4 21.5 3.2
Albania 5.0 2.9 2.9 1.1 31.0 18.8 7.1 5.9 10.8 6.5 0.5 0.6 9.8 5.1 4.3 1.7 50.7 23.3 0.9 0.6 21.8 2.4
Bosnia Herzegovina 2.5 1.0 3.0 1.0 13.4 7.3 19.8 11.7 12.6 7.3 3.1 2.7 10.3 5.8 6.7 1.1 65.6 14.0 1.5 0.8 16.9 3.6
Croatia 12.6 1.3 7.0 0.9 17.6 7.4 41.7 20.3 10.6 3.8 3.6 4.1 13.3 8.6 7.2 0.5 80.2 18.7 4.2 2.7 24.5 4.3
Cyprus 1.4 0.2 1.8 0.5 7.5 4.6 13.6 8.4 5.5 2.3 0.9 1.2 9.5 5.3 2.9 0.2 36.8 8.6 1.7 0.6 21.4 2.5
Greece 2.8 0.8 2.2 0.3 9.6 4.6 14.9 9.9 10.8 4.0 2.1 1.5 10.8 7.1 4.1 0.3 67.7 11.8 1.6 0.9 21.0 2.5
Italy 4.5 1.4 3.0 0.7 12.0 6.1 21.3 13.6 12.8 4.5 2.9 2.9 11.3 8.5 3.3 0.3 52.4 15.6 2.6 1.4 22.9 2.1
FYR Macedonia 4.0 1.3 1.5 0.3 30.3 13.3 23.6 16.7 11.1 5.7 0.9 1.9 17.5 6.6 8.0 0.6 91.6 17.5 3.8 2.4 36.3 7.0
Malta 5.9 1.5 3.9 0.7 9.3 2.5 23.2 16.4 5.8 2.1 1.2 0.6 11.7 9.0 2.3 0.0 45.0 7.8 1.8 0.3 26.0 1.2
Montenegro 6.6 1.7 4.8 1.0 15.3 7.6 30.1 17.1 12.7 7.0 3.1 3.4 12.4 8.8 7.6 1.0 82.3 23.4 2.2 1.3 27.6 7.4
Portugal 10.0 1.4 7.3 0.7 19.5 8.9 30.1 14.9 9.5 2.5 2.3 1.3 9.8 5.6 5.4 0.2 39.4 9.1 1.6 1.2 18.4 4.9
Serbia 10.2 2.0 5.4 1.1 14.0 6.3 34.3 17.2 9.8 4.4 2.4 3.1 12.6 9.1 7.7 0.7 88.4 27.3 4.0 2.0 31.5 10.3
Slovenia 9.8 1.6 5.1 0.8 16.2 6.5 36.1 17.8 10.2 3.1 4.1 4.9 13.5 11.1 3.3 0.2 63.6 20.7 4.5 4.3 23.4 4.1
Spain 5.8 1.3 5.2 0.7 10.8 4.9 27.3 13.5 10.3 3.3 1.5 1.5 10.2 6.6 4.3 0.3 60.0 11.3 1.8 1.2 16.7 2.7
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Western Europe 6.9 1.7 7.4 1.8 7.9 4.0 21.2 13.4 9.9 3.2 1.4 1.6 12.2 9.0 2.2 0.3 52.7 21.3 2.9 1.8 23.5 2.4
Austria 6.2 1.7 5.6 0.8 8.3 4.8 21.3 11.8 10.8 4.0 1.5 1.7 13.3 9.7 1.9 0.3 43.6 20.1 4.1 1.9 21.3 2.8
Belgium 7.0 1.6 7.6 2.1 7.8 3.5 23.8 15.3 6.4 2.9 1.0 1.0 10.8 7.9 3.5 0.3 78.0 19.1 2.3 1.7 29.5 2.7
France 8.1 1.7 7.6 1.6 6.7 2.7 20.6 12.9 14.6 3.6 1.1 1.0 12.0 8.0 2.5 0.3 58.7 18.4 2.7 1.6 23.7 2.6
Germany 6.9 1.8 6.6 1.7 8.8 4.8 20.7 13.1 8.1 3.2 1.7 2.0 12.7 9.8 2.0 0.3 47.0 21.1 2.5 1.6 22.7 2.4
Luxembourg 2.5 0.9 6.7 1.3 6.4 3.4 22.0 14.4 14.4 5.9 0.0 0.0 10.8 8.7 1.8 0.0 50.3 21.4 2.3 1.3 19.9 3.6
The Netherlands 3.8 1.6 12.6 3.6 7.6 4.2 25.5 17.8 4.0 1.8 1.4 1.5 11.6 9.3 1.5 0.4 59.6 35.6 4.5 3.4 26.0 2.1
Switzerland 6.0 1.8 6.6 1.6 5.1 3.1 20.3 10.1 10.0 2.7 1.4 1.9 9.6 8.5 1.9 0.3 38.1 22.6 4.9 2.4 19.8 1.6
Corpus Ovary Prostate Testis Kidney Bladder Brain Thyroid Hodgkin NHL Multiple
myeloma
Leukaemia All sites
C54 C56 C61 C62 C64–66 C67 C70–72 C73 C81 C82–
85,C96
C88 + C90 C91–95 C00–96/C44
F F M M M F M F M F M F M F M F M F M F M F
Europe 3.9 7.6 19.3 0.4 7.2 2.8 8.5 1.8 6.0 4.0 0.5 0.7 0.6 0.4 4.6 2.7 2.7 1.8 6.7 3.9 222.5 128.8
EU-27 3.3 7.4 18.9 0.3 6.7 2.7 8.4 2.0 6.0 4.0 0.4 0.5 0.5 0.3 4.9 3.0 3.0 2.1 6.7 4.0 211.8 128.4
Central and Eastern Europe 4.9 8.3 18.9 0.6 8.4 3.0 9.7 1.4 6.0 4.1 0.6 0.9 0.9 0.5 3.6 2.1 1.7 1.3 6.2 3.7 253.8 130.6
Belarus 5.3 7.5 20.7 0.9 9.6 3.4 7.8 0.8 5.3 3.3 0.5 0.7 1.2 0.6 3.6 2.0 2.2 1.8 8.7 4.7 268.9 111.9
Bulgaria 5.5 8.0 17.2 1.0 7.2 2.5 9.3 1.7 8.4 5.4 0.5 0.4 1.0 0.4 4.2 2.9 1.2 0.9 4.9 3.4 231.7 126.3
Czech Republic 4.0 9.0 20.5 0.5 10.9 4.7 8.3 2.5 5.7 4.0 0.5 0.5 0.4 0.2 4.4 2.7 2.4 2.0 6.7 4.3 241.3 142.4
Hungary 2.3 8.1 17.9 1.0 8.0 2.6 9.9 2.9 4.5 3.1 0.6 0.6 0.4 0.2 4.6 2.9 1.7 1.2 7.8 4.6 306.3 163.6
Moldova 4.1 5.6 15.6 0.6 4.6 1.7 8.6 1.3 4.8 3.2 0.5 0.6 1.0 0.5 4.2 2.7 1.1 0.9 3.9 2.9 231.9 123.4
Poland 4.5 10.2 20.8 0.6 8.5 3.4 12.8 2.1 7.6 5.8 0.4 0.6 0.6 0.4 4.2 2.6 2.8 2.2 7.3 4.1 264.9 146.5
Romania 2.4 7.0 16.3 0.5 5.2 1.9 10.0 1.6 7.7 5.2 0.5 0.7 0.5 0.4 3.5 2.2 1.5 1.1 5.9 3.5 252.9 126.7
Russian Federation 5.2 8.1 19.9 0.6 9.0 3.2 9.2 1.2 5.5 3.8 0.8 1.3 1.0 0.6 3.5 2.0 1.5 1.2 5.7 3.6 258.2 130.5
Slovakia 5.4 8.0 22.3 0.6 9.1 4.1 7.6 1.8 7.3 4.9 0.4 0.5 0.7 0.3 4.3 2.7 2.1 2.0 7.3 4.3 261.4 137.5
Ukraine 5.8 7.9 15.7 0.6 7.9 2.5 9.0 0.8 5.2 3.3 0.5 0.7 1.1 0.8 3.0 1.6 1.1 0.7 6.1 3.5 228.1 115.9
Northern Europe 3.5 8.7 25.2 0.2 6.3 3.0 7.4 2.5 6.3 4.0 0.4 0.4 0.4 0.3 5.3 3.4 3.6 2.3 6.2 3.7 195.9 141.9
Denmark 3.7 9.5 33.7 0.4 6.1 2.9 9.8 3.8 6.6 4.7 0.4 0.4 0.5 0.2 4.7 3.7 3.8 2.0 6.5 4.3 222.3 167.6
Estonia 2.9 7.5 32.8 0.4 9.0 3.5 9.5 1.3 7.2 5.3 0.4 0.8 0.5 0.2 2.5 1.7 3.1 2.1 8.7 4.4 243.4 109.0
Finland 3.5 7.2 21.1 0.1 4.9 2.8 5.3 1.2 5.1 3.8 0.4 0.4 0.4 0.2 5.5 3.8 3.8 2.4 5.4 2.8 163.5 109.2
Iceland 2.0 5.3 26.8 0.0 7.2 3.1 8.0 1.1 6.5 5.4 1.1 0.6 0.0 0.4 4.3 1.7 3.2 2.1 5.9 2.4 161.1 121.4
Ireland 3.7 10.2 22.1 0.2 6.5 3.0 5.6 2.1 6.9 4.6 0.4 0.3 0.5 0.3 5.8 3.8 3.9 2.4 7.1 3.8 193.1 145.6
Latvia 7.1 12.4 30.2 0.5 10.9 4.6 13.2 1.5 8.0 5.7 0.4 0.9 0.8 0.7 5.0 3.4 2.7 2.0 6.4 4.2 276.5 139.1
Lithuania 4.8 11.9 36.1 0.3 12.6 3.8 11.0 1.6 7.3 5.5 0.6 0.6 0.5 0.3 4.8 2.5 3.2 2.2 8.2 5.1 291.1 129.7
Norway 2.9 9.4 32.0 0.4 6.0 2.0 7.1 2.3 6.5 4.3 0.5 0.5 0.2 0.1 5.3 3.3 4.5 2.8 5.6 3.5 182.0 134.3
Sweden 3.2 8.2 31.6 0.2 5.5 2.8 6.5 2.1 6.4 4.3 0.4 0.5 0.2 0.2 4.5 2.8 3.8 2.6 5.9 3.9 162.0 129.9
United Kingdom 3.3 8.4 22.8 0.2 6.2 3.1 7.3 2.8 6.2 3.7 0.3 0.4 0.5 0.4 5.6 3.6 3.6 2.3 6.2 3.6 196.9 147.5
Southern Europe 3.3 6.4 16.2 0.3 5.5 2.0 9.9 1.8 6.3 4.2 0.4 0.5 0.6 0.4 4.8 2.8 2.8 2.1 7.0 4.1 212.0 118.0
Albania 3.0 2.0 13.4 0.5 5.4 2.6 9.2 2.7 12.3 7.8 0.4 0.4 0.9 0.2 0.9 0.5 0.3 0.4 5.3 4.4 193.4 138.1
Bosnia Herzegovina 3.5 5.9 15.1 0.8 3.4 1.4 7.5 1.9 5.0 3.6 0.2 0.9 0.8 0.3 2.8 1.2 0.7 0.6 2.6 2.2 188.7 104.0
Croatia 4.5 9.3 26.0 0.8 9.7 2.8 9.7 2.0 8.1 5.8 0.5 0.5 0.5 0.3 5.2 3.7 2.1 2.1 6.9 4.4 287.5 143.1
Cyprus 3.1 5.8 17.9 0.3 1.8 1.1 6.7 1.2 4.0 3.0 0.7 0.6 0.4 0.3 4.7 3.1 3.0 1.9 6.7 3.6 148.7 96.2
Greece 2.6 6.2 17.7 0.4 4.7 1.8 9.8 1.6 8.2 5.9 0.4 0.4 1.5 0.9 1.7 1.0 2.2 1.6 9.2 5.3 203.6 107.4
Italy 3.2 6.8 14.1 0.2 5.9 2.1 8.7 1.5 5.8 3.6 0.5 0.5 0.6 0.3 5.7 3.3 3.2 2.4 7.5 4.3 200.1 122.4
(continued on next page)
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and Greece (289, 192). Mortality rates reﬂect the fre-
quency and the fatality of cancer, both high in men in
Eastern and Central European countries e.g. Hungary
(306). The high all-cancer mortality rate estimated in
Danish women (168) is partially driven by the high inci-
dence and mortality rates of breast cancer. The lowest
mortality rates in males were estimated for Northern
European countries, Finland (163) and Iceland (161),
and in females for Southern European countries, Portu-
gal (103) and Spain (99) (Figs. 3c, d and 4b).3.2. Breast cancer
Breast cancer was the leading cancer site in women in
all countries of Europe (Table 4) in 2012. There is a 3-
fold variation (49–148 per 100,000) with a clear geo-
graphical pattern (Fig. 5). High incidence rates were esti-
mated in Western European countries, notably in
Belgium (147), France (137) and The Netherlands
(131) and in Northern Europe, particularly in the Uni-
ted Kingdom (129) and in the Nordic countries, Den-
mark (143), Iceland (131) and Finland (121). In
comparison, incidence rates in Eastern European coun-
tries such as the Ukraine (54) and Moldova (53) were
much lower. The range of mortality rates varies twofold
(15–36 per 100,000). Mortality rates were highest in the
North (e.g. Belgium, 29 and Denmark, 28) and in the
South (e.g. Serbia, 31 and Macedonia, 36). The high
mortality rates in the northern countries reﬂect the high
incidence, while in the south there is a high mortality to
incidence ratio, a proxy of unfavourable survival
(Fig. 5).3.3. Colorectal cancer
The incidence rates of colorectal cancer are slightly
higher in men than in women (Fig. 6a). Elevated rates
of incidence were estimated in Central European coun-
tries — Slovakia (92 per 100,000), Hungary (87) and
Czech Republic (81) in men, and in Norway (54), Den-
mark (53) and The Netherlands (50) in women. There is
up to a ﬁvefold variation in the incidence rates across
Europe, with the lowest rates in the Balkan countries
of Bosnia Herzegovina (30 in men, 19 in women),
Greece (25, 17) and Albania (13, 11). Geographical pat-
terns of mortality partially follow incidence, although
mortality is high also in some countries with relatively
low incidence rates (Moldova, Russia, Montenegro,
Poland and Lithuania) (Fig. 6a and 6b).3.4. Prostate cancer
Incidence rates of prostate cancer vary by more than
7-fold (25–193 per 100,000) the highest rates were esti-
mated in Northern and Western European countries
Table 7a
Estimated number of new cancer cases (hundreds) by sex, cancer site and country, 2012.
Oral cavity and
pharynx
Oesophagus Stomach Colon and rectum Liver Gallbladder Pancreas Larynx Lung Melanoma Breast Cervix
C00–14 C15 C16 C18–21 C22 C23–24 C25 C32 C33–34 C43 C50 C53
M F M F M F M F M F M F M F M F M F M F F F
Europe 738.6 257.7 350.7 107.8 841.8 554.1 2416.2 2051.8 427.8 206.4 118.8 178.6 519.2 518.5 359.8 39.2 2907.1 1192.1 472.4 531.0 4638.2 583.5
EU-27 533.7 196.5 259.9 85.5 499.3 306.9 1916.2 1505.1 355.6 157.6 96.1 139.4 390.8 395.7 248.5 31.0 2114.0 981.9 395.7 425.0 3644.5 333.5
Central and Eastern Europe 290.3 79.5 110.4 26.1 410.8 285.7 703.2 695.4 94.8 64.8 33.6 65.8 177.7 168.9 153.3 11.7 1069.6 316.5 86.2 118.5 1236.2 338.8
Belarus 10.8 1.6 4.1 0.4 17.7 11.9 18.9 21.2 2.0 1.3 0.8 1.4 4.4 3.7 5.3 0.2 34.2 5.9 2.1 3.6 37.8 9.2
Bulgaria 6.5 2.0 1.8 0.4 9.9 6.7 27.1 22.1 4.2 2.2 1.3 1.8 6.9 5.5 6.0 0.3 32.5 6.9 2.3 2.1 39.3 12.5
Czech Republic 10.7 4.4 4.8 1.1 9.4 6.5 49.8 33.6 5.8 3.4 3.3 6.4 10.9 10.3 4.8 0.5 46.2 20.6 11.5 10.5 68.5 10.2
Hungary 20.6 6.4 5.1 1.0 11.2 8.4 47.5 36.9 4.3 2.0 2.3 4.1 9.1 9.5 8.7 1.2 58.9 34.0 5.7 5.5 50.9 11.8
Moldova 3.7 0.7 0.8 0.1 4.1 2.0 8.0 7.2 2.8 1.7 0.1 0.3 2.2 2.2 2.6 0.1 9.8 2.6 0.5 0.7 11.0 4.8
Poland 37.9 12.2 11.5 3.6 39.4 21.7 110.7 83.7 10.7 9.3 6.2 16.8 25.5 24.6 23.4 3.2 179.1 83.3 11.9 13.9 172.6 35.1
Romania 32.4 4.9 6.6 1.1 27.1 13.6 57.6 45.0 14.9 7.3 2.6 3.7 16.9 13.9 15.4 0.8 93.2 23.3 5.3 5.9 89.8 43.4
Russian Federation 112.7 35.3 57.2 15.4 218.4 165.8 267.5 331.8 38.5 29.6 12.2 21.9 72.1 73.1 60.2 4.0 456.0 102.1 32.1 55.0 575.0 153.4
Slovakia 8.2 1.7 2.4 0.4 5.3 3.7 23.5 16.2 2.6 1.4 1.3 2.6 4.4 4.4 2.6 0.2 18.0 7.3 4.0 4.1 26.4 6.1
Ukraine 46.7 10.5 16.2 2.6 68.3 45.4 92.7 97.8 9.0 6.6 3.6 6.8 25.5 21.8 24.3 1.1 141.8 30.7 10.8 17.1 164.7 52.3
Northern Europe 76.7 39.6 76.0 34.7 71.8 44.5 351.7 298.1 41.9 22.5 7.7 13.9 69.2 72.8 28.9 5.6 333.6 266.3 112.1 120.3 780.2 53.7
Denmark 6.1 3.0 3.0 1.5 4.4 1.9 25.4 23.0 2.3 0.8 1.1 1.4 5.1 5.1 2.1 0.5 23.0 22.6 7.3 8.7 52.2 3.6
Estonia 1.0 0.4 0.4 0.1 2.0 1.7 3.7 4.2 0.3 0.3 0.2 0.3 1.0 0.9 0.5 0.0 4.8 1.5 0.6 1.1 6.6 1.9
Finland 3.4 2.4 1.9 0.9 3.7 2.7 15.5 13.5 4.1 2.1 1.1 1.5 5.6 6.0 1.0 0.1 16.8 8.1 6.7 5.4 44.8 1.4
Iceland 0.2 0.1 0.2 0.1 0.2 0.1 0.8 0.8 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.8 0.8 0.2 0.3 2.3 0.1
Ireland 2.6 1.2 2.8 1.4 3.1 1.8 14.8 10.8 1.5 0.9 0.6 0.9 2.6 2.5 1.5 0.3 12.5 10.3 4.0 4.6 29.0 3.6
Latvia 1.7 0.5 1.1 0.3 3.8 2.6 5.3 6.3 1.0 0.6 0.2 0.4 1.7 2.0 1.3 0.1 9.5 2.4 0.9 1.4 11.5 2.8
Lithuania 3.0 0.8 1.7 0.3 5.4 3.3 7.7 7.9 1.1 0.6 0.4 0.6 2.5 2.3 1.7 0.1 12.8 2.8 1.2 1.6 14.8 6.2
Norway 3.1 2.2 1.7 0.6 2.7 2.1 19.7 19.5 1.2 0.7 0.8 0.8 3.6 3.7 1.0 0.2 15.7 12.8 7.7 7.4 28.9 2.9
Sweden 5.8 3.9 3.4 1.2 5.0 3.1 33.0 30.6 3.2 1.7 1.4 2.3 4.8 4.8 1.5 0.3 19.3 19.6 14.6 14.6 66.2 4.5
United Kingdom 50.0 25.0 59.7 28.3 41.7 25.2 226.0 181.6 27.2 14.7 2.0 5.5 42.1 45.4 18.1 3.9 218.5 185.4 69.0 75.5 524.0 26.6
Southern Europe 126.7 48.7 45.1 11.2 182.9 120.7 599.7 449.5 141.2 64.2 36.0 44.9 115.4 115.1 96.2 9.1 698.7 217.5 92.7 99.6 1007.2 92.8
Albania 1.3 0.8 0.3 0.2 5.0 3.4 1.8 1.7 1.0 0.7 0.1 0.1 1.3 0.7 0.9 0.4 7.3 3.7 0.2 0.2 10.2 0.9
Bosnia Herzegovina 1.9 1.0 0.5 0.2 3.1 2.2 6.2 4.9 1.7 1.4 0.7 0.9 1.5 1.1 2.3 0.4 13.4 3.9 0.5 0.5 11.5 3.6
Croatia 5.2 1.7 2.0 0.4 5.9 3.8 18.0 14.1 3.3 1.4 1.2 2.2 3.5 3.3 3.4 0.4 22.6 7.9 3.1 3.6 26.4 3.3
Cyprus 0.2 0.1 0.1 0.1 0.6 0.3 2.3 2.1 0.4 0.2 0.1 0.2 0.4 0.4 0.2 0.0 2.1 0.7 0.3 0.3 6.0 0.3
Greece 4.0 1.7 1.8 0.4 9.0 5.8 20.7 18.1 7.1 3.5 2.1 2.0 8.3 7.1 4.8 0.4 56.8 12.0 2.6 2.1 49.3 4.2
Italy 38.4 20.0 13.4 4.7 75.5 54.5 265.7 215.4 71.9 35.5 16.7 22.8 49.5 57.4 37.1 3.4 269.3 103.1 48.9 51.2 506.6 29.2
FYR Macedonia 0.7 0.3 0.2 0.0 3.5 1.9 4.2 3.7 0.9 0.5 0.2 0.3 1.7 0.8 1.3 0.1 10.4 2.2 0.8 0.7 11.5 1.7
Malta 0.4 0.2 0.1 0.1 0.4 0.3 1.5 1.2 0.1 0.1 0.1 0.1 0.4 0.3 0.2 0.1 1.5 0.3 0.2 0.2 3.1 0.1
Montenegro 0.5 0.2 0.1 0.0 0.5 0.3 1.6 1.1 0.3 0.2 0.1 0.2 0.3 0.3 0.4 0.1 2.7 0.9 0.2 0.2 2.6 0.8
Portugal 16.8 4.0 5.3 0.8 18.3 11.8 42.1 29.2 7.7 2.3 3.0 1.9 6.7 5.6 8.0 0.3 32.1 9.8 4.6 6.4 60.9 7.2
Serbia 9.8 3.3 3.0 0.8 9.3 5.3 33.7 21.4 5.2 2.8 1.5 2.5 6.7 5.8 7.4 0.9 52.8 19.9 5.9 4.3 54.2 15.0
Slovenia 2.5 0.8 0.7 0.2 2.9 1.8 9.3 6.9 1.6 0.6 0.7 1.3 1.8 2.1 0.9 0.1 9.8 3.8 2.5 2.8 12.6 1.4
Spain 45.0 14.7 17.6 3.3 48.7 29.4 192.6 129.8 40.1 15.2 9.5 10.6 33.4 30.3 29.1 2.7 217.8 49.4 22.9 27.2 252.2 25.1
(continued on next page)
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Table 7a (continued)
Oral cavity and
pharynx
Oesophagus Stomach Colon and rectum Liver Gallbladder Pancreas Larynx Lung Melanoma Breast Cervix
C00–14 C15 C16 C18–21 C22 C23–24 C25 C32 C33–34 C43 C50 C53
M F M F M F M F M F M F M F M F M F M F F F
Western Europe 244.9 89.9 119.2 35.9 176.3 103.3 761.6 608.9 149.9 55.0 41.4 54.1 157.0 161.6 81.4 12.8 805.2 391.7 181.5 192.6 1614.6 98.2
Austria 8.2 3.3 3.7 0.8 7.6 5.5 27.9 20.8 6.4 3.1 1.5 2.1 7.8 8.0 2.5 0.4 28.5 17.3 6.6 6.7 52.5 3.6
Belgium 13.8 4.9 7.2 2.5 8.8 5.3 48.0 38.9 4.5 2.0 1.7 2.0 6.7 6.3 6.2 1.0 57.6 20.4 7.6 11.8 103.4 6.4
France 80.7 31.7 32.6 11.6 42.6 22.5 215.2 193.0 65.0 18.3 11.6 13.5 45.5 45.9 28.3 5.2 280.3 120.1 47.2 51.5 542.5 28.6
Germany 120.5 38.4 55.4 14.1 100.8 59.3 365.7 270.1 64.0 28.1 21.8 31.6 79.7 84.8 36.1 4.5 341.6 166.5 85.1 83.7 716.2 50.0
Luxembourg 0.5 0.2 0.3 0.1 0.4 0.3 1.8 1.3 0.5 0.2 0.0 0.0 0.3 0.3 0.1 0.0 1.7 0.9 0.4 0.4 3.6 0.2
The Netherlands 12.8 7.9 15.6 5.3 12.3 7.3 76.0 63.2 3.4 1.4 3.4 2.9 11.4 10.0 6.1 1.3 69.9 49.8 22.0 26.1 139.0 7.5
Switzerland 8.4 3.6 4.4 1.6 3.8 3.1 27.1 21.7 6.2 1.9 1.5 1.9 5.5 6.2 2.1 0.3 25.6 16.8 12.5 12.3 57.5 1.9
Corpus Ovary Prostate Testis Kidney Bladder Brain Thyroid Hodgkin NHL Multiple
myeloma
Leukaemia All sites
C54 C56 C61 C62 C64–66 C67 C70–72 C73 C81 C82–
85,C96
C88 + C90 C91–95 C00–96/C44
F F M M M F M F M F M F M F M F M F M F M F
Europe 989.2 655.4 4167.3 215.3 717.4 434.4 1182.8 329.1 307.2 263.8 122.8 406.5 92.8 83.0 495.3 439.0 204.9 184.4 464.1 358.6 18290.7 16105.3
EU-27 643.3 441.5 3599.4 180.1 537.6 306.3 964.4 266.9 231.3 194.2 96.1 272.5 66.6 56.2 422.4 365.3 179.4 154.8 359.5 262.8 14342.6 12003.2
Central and Eastern Europe 420.3 282.6 654.3 49.1 238.0 165.5 308.7 89.0 98.5 96.9 31.6 159.6 30.2 30.7 87.7 93.3 31.6 39.7 131.7 117.2 5137.8 5230.9
Belarus 14.3 8.4 21.4 1.3 9.3 6.5 8.7 2.1 2.4 2.6 1.9 9.1 1.2 1.4 2.6 2.4 1.2 1.7 5.7 5.0 164.4 159.8
Bulgaria 12.8 9.0 18.2 2.2 5.8 3.0 12.8 3.8 4.4 3.9 0.5 2.6 0.8 0.7 2.8 2.6 1.2 1.2 3.4 2.7 164.8 155.7
Czech Republic 18.9 10.9 68.5 5.0 21.2 12.0 17.7 6.9 4.2 4.2 2.1 8.8 1.5 1.0 6.3 6.4 2.3 2.0 5.7 4.5 307.2 269.1
Hungary 7.9 10.0 31.7 5.7 10.3 5.3 18.7 8.2 3.0 3.0 1.5 5.3 0.8 0.7 4.7 5.2 1.2 1.4 5.9 5.2 269.7 235.0
Moldova 3.5 2.0 4.4 0.4 1.4 0.9 2.7 0.8 1.0 0.8 0.4 1.5 0.3 0.2 1.1 1.1 0.2 0.3 1.0 0.8 50.8 48.1
Poland 59.1 44.6 110.3 9.4 30.5 21.9 61.1 18.5 20.9 23.8 3.5 14.2 4.2 3.1 12.2 14.4 6.1 8.1 18.9 14.1 777.1 745.1
Romania 15.4 18.5 45.3 3.4 12.5 6.9 31.5 6.7 9.2 8.0 1.3 6.6 1.4 1.8 8.0 7.7 3.2 3.2 10.1 7.4 431.5 356.1
Russian Federation 209.7 133.7 268.9 13.3 109.2 83.9 107.9 30.6 37.6 36.1 15.0 86.8 14.0 15.1 36.8 40.4 11.6 15.8 58.7 59.0 2154.2 2429.6
Slovakia 9.3 5.2 19.3 2.8 6.5 4.1 7.2 2.2 2.7 2.5 0.7 2.3 0.6 0.7 2.7 3.1 1.2 1.6 3.8 2.7 126.1 114.3
Ukraine 69.3 40.3 66.4 5.7 31.4 21.0 40.3 9.3 13.2 12.0 4.8 22.4 5.5 5.9 10.5 10.1 3.5 4.3 18.6 15.8 692.0 718.0
Northern Europe 137.6 99.9 814.4 36.3 95.1 58.9 126.8 46.3 47.3 37.6 11.8 37.5 14.5 11.0 97.7 82.4 39.1 31.4 73.0 51.9 2708.0 2535.0
Denmark 7.5 5.4 52.0 3.4 4.9 2.6 13.1 4.7 2.9 2.3 0.7 1.5 0.7 0.6 5.7 4.6 1.7 1.5 3.5 2.4 185.6 175.6
Estonia 2.0 1.6 10.2 0.2 1.7 1.2 1.5 0.6 0.5 0.4 0.2 0.7 0.2 0.1 0.7 0.6 0.3 0.3 0.9 0.9 32.4 28.8
Finland 8.6 4.6 53.7 1.4 4.8 4.1 8.7 2.2 2.4 1.9 1.0 2.9 0.8 0.6 6.4 5.7 2.0 1.6 3.7 2.8 152.0 132.2
Iceland 0.3 0.2 2.7 0.1 0.3 0.2 0.5 0.2 0.1 0.1 0.1 0.2 0.0 0.0 0.3 0.2 0.1 0.1 0.2 0.1 7.6 6.9
Ireland 3.7 3.8 37.9 2.2 3.5 2.2 4.7 2.0 2.0 1.5 0.4 1.1 0.7 0.6 3.9 3.2 1.6 1.3 3.9 2.1 113.0 95.0
Latvia 3.9 3.0 14.8 0.6 2.6 1.9 3.0 1.2 1.2 1.4 0.3 1.3 0.2 0.2 0.9 1.0 0.4 0.5 1.3 1.3 53.9 49.6
Lithuania 5.7 3.7 15.2 0.3 4.7 3.1 3.9 1.8 1.3 1.8 0.8 4.9 0.3 0.3 1.6 1.9 0.8 1.1 2.1 2.2 72.5 72.7
Norway 7.7 4.2 57.9 3.1 5.1 2.8 10.2 3.6 3.0 2.6 0.8 1.9 0.8 0.5 5.0 4.1 2.6 1.9 3.5 2.5 158.6 123.6
Sweden 14.3 6.6 116.0 3.3 6.8 4.4 17.8 5.7 5.8 7.3 1.0 2.9 1.0 0.7 8.8 7.2 3.5 2.8 6.4 5.1 277.4 227.5
United Kingdom 83.8 66.9 454.1 21.6 60.7 36.5 63.5 24.3 28.0 18.6 6.5 20.0 9.8 7.2 64.5 53.9 26.1 20.4 47.6 32.5 1655.0 1623.1
Southern Europe 195.0 128.6 912.7 47.8 153.9 76.2 347.6 80.4 76.9 62.9 38.2 99.3 22.1 18.3 127.2 104.3 50.8 45.9 111.5 81.4 4300.8 3384.6
Albania 2.2 0.6 3.4 0.8 1.5 0.8 3.1 1.1 2.2 1.6 0.2 0.4 0.3 0.1 0.2 0.1 0.0 0.1 1.0 0.9 36.4 35.0
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in Central and Eastern European countries – Republic
of Moldova (30) and Albania (25). In comparison with
incidence, mortality rates vary much less, from the high-
est estimated rates in Lithuania (36) or Denmark (34) to
the lowest in Malta (14) or Albania (13) (Fig. 7).3.5. Lung cancer
In men, incidence was highest in Central and Eastern
European countries – Hungary (109), FYR of Macedo-
nia (102), Serbia (99) and Poland (90) and lowest in the
Northern European countries, for example in Finland
(45) and Sweden (29). The reverse was seen in women:
elevated rates were estimated in Northern Europe (e.g.
Denmark (55) and The Netherlands (44)) and low rates
in Eastern Europe (e.g. Ukraine and Belarus (9) or Rus-
sian Federation (10)). For both sexes combined the
highest rates were seen in Hungary and the lowest in
Cyprus (Fig. 8). Geographical patterns of mortality
are quite similar to those of incidence for both sexes
(Table 6b), due to the rapid course of the disease after
diagnosis. Lung cancer is the leading cause of cancer
death amongst men in all countries except Sweden,
and women die from lung cancer more commonly than
from breast cancer in a growing number of countries
(Table 4).4. Discussion
This timely and comparative situation analysis of the
cancer burden in Europe reveals variations in incidence
and mortality rates. These reﬂect variability in the
national health system policies (e.g. organised screening
for breast, prostate, cervical and colorectal cancers), the
varying prevalence – of risk factors between countries
and regions, and disparities in human development
and the eﬀective delivery of cancer control measures.
Strategies to reduce the extent of the disease burden
on the continent evidently need to be established locally,
to reﬂect the proﬁle of the observed cancer rates in each
European country and in comparison with the pattern in
other countries. We estimated 3.45 million new cases
and 1.75 million deaths from cancer in Europe in
2012. In combination, cancers of the female breast, colo-
rectal, prostate and lung represent almost half of the
overall burden of cancer in Europe. The same diseases
are also major causes of cancer death in Europe in
2012, with stomach and pancreatic cancer ranking 4th
and 5th respectively, ahead of prostate cancer.
Since the annual statistics published by cancer regis-
tries need 2–5 years to be ﬁnalised, the short-term pre-
dictions are the best alternative to provide up-to-date
ﬁgures to timely inform cancer control policies. Addi-
tional estimations were required where national inci-
dence data were not available, using incidence and
Table 7b
Estimated number of cancer deaths (hundreds) by sex, cancer site and country, 2012.
Oral cavity and
pharynx
Oesophagus Stomach Colon and
rectum
Liver Gallbladder Pancreas Larynx Lung Melanoma Breast Cervix
C00–14 C15 C16 C18–21 C22 C23–24 C25 C32 C33–34 C43 C50 C53
M F M F M F M F M F M F M F M F M F M F F F
Europe 342.5 94.1 303.1 91.9 636.1 436.6 1131.6 1015.1 398.9 222.5 78.9 129.8 525.8 518.8 180.7 17.0 2544.4 990.2 120.5 101.5 1311.7 243.8
EU-27 214.8 67.0 222.4 73.8 348.8 227.8 818.0 681.8 315.9 164.0 61.3 98.5 388.9 390.6 107.7 12.8 1833.7 814.1 88.1 69.2 905.8 129.8
Central and
Eastern
Europe
179.7 37.0 98.9 21.4 343.1 239.8 425.5 419.3 108.1 76.1 26.6 52.7 180.5 169.7 97.6 6.3 956.9 263.0 38.5 39.7 487.2 154.4
Belarus 7.1 0.7 3.8 0.3 15.0 9.9 10.8 11.4 1.9 1.0 0.5 0.6 4.8 3.6 3.8 0.1 30.4 3.8 1.1 1.4 12.6 3.7
Bulgaria 4.2 1.6 1.6 0.3 8.3 5.2 15.2 12.1 5.3 3.3 0.7 1.0 6.0 4.5 4.1 0.3 30.2 6.4 1.1 0.8 13.9 4.4
Czech
Republic
5.6 1.6 3.9 0.8 6.5 4.5 21.8 14.5 4.4 2.6 2.6 5.0 9.5 9.8 2.1 0.2 36.6 15.7 2.0 1.4 16.2 3.1
Hungary 12.0 2.6 4.5 0.9 8.9 6.8 25.9 20.7 4.1 2.1 1.9 3.5 8.9 9.4 4.5 0.6 52.4 28.3 1.9 1.5 19.1 4.6
Moldova 2.5 0.3 0.7 0.1 3.4 1.6 4.9 4.1 3.1 1.9 0.1 0.2 2.1 1.8 1.7 0.1 8.3 2.0 0.3 0.2 5.5 2.1
Poland 19.2 5.2 11.1 3.1 33.7 18.3 63.7 49.8 11.0 9.6 5.1 13.9 24.6 23.9 13.1 1.8 165.3 68.4 7.0 6.5 53.7 18.6
Romania 19.6 2.4 6.0 1.1 22.2 11.5 32.3 24.5 18.2 10.1 2.0 2.6 15.5 12.4 9.5 0.6 80.2 20.5 1.9 1.8 32.4 19.1
Russian
Federation
73.2 17.4 52.1 12.9 185.4 143.1 181.2 217.9 48.5 36.8 10.0 18.4 81.7 82.0 41.2 1.9 418.9 90.0 16.9 19.4 245.4 73.7
Slovakia 5.4 0.8 2.2 0.4 3.7 2.7 10.5 7.4 2.1 1.3 1.0 1.9 3.8 4.4 1.6 0.1 15.1 4.7 1.0 0.9 7.0 2.3
Ukraine 30.9 4.5 13.1 1.6 56.0 36.1 59.3 57.0 9.5 7.3 2.8 5.5 23.8 17.9 16.1 0.6 119.5 23.2 5.4 5.8 81.2 22.7
Northern
Europe
26.4 12.5 69.3 31.1 48.8 31.7 141.2 125.7 38.8 24.1 6.3 11.0 69.3 72.9 11.6 2.0 294.2 227.7 22.7 16.6 177.7 19.4
Denmark 2.5 1.1 3.6 1.3 2.2 1.3 10.2 9.8 2.3 0.7 0.5 0.7 4.6 4.2 0.9 0.2 20.0 18.1 1.3 1.0 12.0 1.0
Estonia 0.5 0.2 0.5 0.1 1.3 1.2 2.0 1.8 0.4 0.3 0.1 0.3 1.0 1.1 0.3 0.0 4.1 1.3 0.3 0.3 1.7 0.6
Finland 1.1 0.7 1.6 0.8 2.7 2.1 6.1 5.5 3.0 1.9 0.8 1.3 5.0 5.5 0.3 0.1 14.7 6.6 1.5 0.7 8.6 0.5
Iceland 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.2 0.1 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.7 0.7 0.1 0.1 0.4 0.0
Ireland 1.0 0.4 2.4 1.2 2.0 1.2 5.9 4.0 1.3 1.0 0.2 0.3 2.5 2.4 0.6 0.1 10.5 7.3 0.9 0.5 7.0 1.0
Latvia 1.2 0.3 1.1 0.2 2.8 2.1 3.3 3.6 0.8 0.6 0.2 0.3 1.8 1.9 0.8 0.1 8.4 1.7 0.3 0.5 4.3 1.4
Lithuania 2.4 0.5 1.6 0.3 4.0 2.7 5.0 4.9 1.1 0.7 0.3 0.5 2.4 2.2 1.5 0.1 11.0 1.9 0.6 0.5 6.1 2.2
Norway 0.8 0.5 1.5 0.5 1.6 1.5 7.3 7.8 1.0 0.8 0.2 0.2 3.4 3.6 0.4 0.0 12.5 9.7 2.1 1.2 6.3 1.0
Sweden 2.0 1.2 3.1 1.2 4.0 2.4 13.9 13.4 3.9 2.3 1.7 2.9 7.6 8.8 0.5 0.1 18.3 18.6 3.4 2.3 14.5 1.9
United
Kingdom
15.0 7.6 53.7 25.6 28.2 17.1 87.3 74.7 25.0 15.6 2.4 4.5 41.0 43.1 6.2 1.4 194.0 161.9 12.5 9.5 116.8 9.8
Southern
Europe
54.5 18.7 40.9 10.1 138.3 92.5 271.0 209.6 122.0 63.7 26.1 35.8 115.0 112.3 43.9 4.2 612.9 182.7 23.1 17.3 274.5 35.3
Albania 0.7 0.5 0.4 0.2 4.3 2.9 1.0 0.9 1.5 1.0 0.1 0.1 1.3 0.8 0.6 0.3 6.9 3.6 0.1 0.1 3.2 0.3
Bosnia
Herzegovina
0.5 0.3 0.7 0.3 2.8 2.0 4.2 3.3 2.7 2.1 0.7 0.7 2.1 1.6 1.4 0.3 13.6 3.7 0.3 0.2 4.3 0.9
Croatia 3.2 0.5 1.8 0.4 4.8 3.1 11.5 8.6 2.8 1.6 1.0 1.7 3.6 3.5 1.9 0.2 21.2 6.7 1.1 1.0 9.2 1.4
Cyprus 0.1 0.0 0.1 0.0 0.4 0.3 0.8 0.6 0.3 0.2 0.1 0.1 0.5 0.3 0.2 0.0 2.0 0.5 0.1 0.0 1.3 0.2
Greece 2.1 0.9 1.7 0.4 8.1 5.2 13.5 11.8 9.2 4.8 1.8 1.7 8.6 7.7 3.3 0.3 53.0 11.4 1.2 0.8 21.4 2.1
Italy 18.6 8.4 13.1 4.4 57.2 41.9 102.5 90.3 60.1 31.9 14.0 19.7 50.7 55.6 15.0 1.5 246.9 88.5 10.7 7.4 128.0 10.2
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Macedonia
0.4 0.2 0.2 0.0 3.1 1.7 2.4 2.1 1.1 0.7 0.1 0.2 1.8 0.8 0.8 0.1 9.4 2.1 0.4 0.3 4.3 0.8
Malta 0.2 0.1 0.1 0.0 0.2 0.1 0.6 0.5 0.2 0.1 0.0 0.0 0.3 0.3 0.1 0.0 1.2 0.2 0.1 0.0 0.8 0.0
Montenegro 0.2 0.1 0.2 0.0 0.5 0.3 1.0 0.7 0.4 0.3 0.1 0.1 0.4 0.3 0.2 0.0 2.6 0.9 0.1 0.1 1.0 0.3
Portugal 6.2 1.3 4.7 0.7 13.9 9.0 22.4 15.6 6.6 2.5 1.7 1.4 6.9 5.8 3.5 0.2 26.4 8.0 1.1 1.1 15.7 3.9
Serbia 5.4 1.4 2.9 0.7 7.7 4.3 19.2 12.1 5.4 3.1 1.4 2.1 7.0 6.3 4.1 0.5 47.5 16.9 2.1 1.3 20.4 6.1
Slovenia 1.2 0.3 0.6 0.2 2.0 1.3 4.6 3.5 1.3 0.6 0.5 1.0 1.7 2.1 0.4 0.0 8.0 3.4 0.6 0.7 4.2 0.6
Spain 15.8 4.9 14.6 2.7 33.4 20.5 87.4 59.6 30.5 14.9 4.8 6.9 30.0 27.2 12.4 0.9 174.3 36.9 5.3 4.4 60.8 8.5
Western
Europe
81.9 25.9 94.0 29.4 105.9 72.6 294.0 260.6 130.0 58.6 19.9 30.3 160.9 164.0 27.7 4.5 680.4 316.8 36.2 27.8 372.3 34.8
Austria 3.2 1.1 2.9 0.6 4.7 3.9 12.1 9.8 5.9 3.1 0.9 1.4 7.3 7.6 1.0 0.2 23.4 13.2 2.2 1.3 15.1 1.8
Belgium 4.5 1.3 5.2 2.0 5.9 3.8 18.4 16.7 4.6 3.0 0.8 1.1 7.9 8.0 2.4 0.3 56.4 15.4 1.6 1.4 25.2 2.2
France 29.7 7.9 30.0 8.3 28.5 15.7 89.9 81.6 59.3 21.2 4.8 6.5 49.1 46.8 9.7 1.3 229.1 85.3 10.6 7.8 119.3 11.7
Germany 37.7 12.5 39.0 12.7 55.8 41.3 134.6 120.1 50.5 26.7 11.2 17.9 79.0 82.9 12.0 2.1 287.0 147.2 14.7 12.0 168.3 15.7
Luxembourg 0.1 0.0 0.2 0.1 0.2 0.1 0.7 0.6 0.4 0.2 0.0 0.0 0.3 0.3 0.1 0.0 1.5 0.7 0.1 0.0 0.7 0.1
The
Netherlands
3.9 2.0 13.4 4.7 8.2 5.7 27.6 24.8 4.3 2.5 1.5 2.0 12.4 12.5 1.6 0.5 63.9 42.2 4.6 3.9 31.6 2.4
Switzerland 2.9 1.1 3.3 1.1 2.6 2.2 10.7 7.2 5.0 1.9 0.7 1.3 4.9 5.9 0.9 0.2 19.1 12.9 2.4 1.4 12.0 0.9
Corpus Ovary Prostate Testis Kidney Bladder Brain Thyroid Hodgkin NHL Multiple
myeloma
Leukaemia All sites
C54 C56 C61 C62 C64–66 C67 C70–72 C73 C81 C82–85,C96 C88 + C90 C91–95 C00–96/C44
F F M M M F M F M F M F M F M F M F M F M F
Europe 237.2 427.0 922.4 16.1 312.9 176.6 394.9 128.7 245.5 204.3 20.7 42.7 26.2 20.0 203.3 175.3 122.2 120.7 294.9 242.7 9759.2 7786.3
EU-27 146.8 297.6 710.2 9.1 222.8 124.4 299.1 103.4 180.1 145.5 13.6 22.5 15.3 11.4 163.8 140.3 103.9 99.3 229.2 181.9 7075.0 5549.3
Central and
Eastern
Europe
107.2 168.1 258.6 9.0 117.0 68.5 132.3 35.4 84.7 78.6 8.4 22.8 12.6 9.9 50.7 45.6 23.6 28.8 85.9 78.9 3512.3 2869.6
Belarus 3.6 4.8 8.3 0.4 4.1 2.3 3.2 0.7 2.4 2.0 0.2 0.5 0.5 0.4 1.5 1.4 0.9 1.2 3.6 3.3 112.8 77.5
Bulgaria 3.2 4.4 8.6 0.4 3.2 1.5 4.4 1.2 3.6 2.9 0.2 0.3 0.4 0.2 1.8 1.6 0.5 0.5 2.1 1.9 105.5 75.1
Czech
Republic
3.5 7.1 12.7 0.3 6.7 4.3 5.1 2.3 3.4 3.0 0.3 0.4 0.2 0.2 2.7 2.4 1.5 1.8 4.1 3.8 148.0 121.1
Hungary 2.1 6.4 10.3 0.5 4.4 2.4 5.6 2.6 2.4 2.3 0.3 0.5 0.2 0.2 2.5 2.5 0.9 1.1 4.3 4.0 167.6 134.9
Moldova 0.9 1.2 2.2 0.1 0.7 0.4 1.3 0.3 0.8 0.6 0.1 0.1 0.2 0.1 0.7 0.6 0.2 0.2 0.6 0.6 36.4 26.5
Poland 13.1 26.9 42.4 1.2 16.9 10.3 25.8 6.9 15.1 15.2 0.8 1.8 1.3 0.9 8.3 7.4 5.6 6.6 14.6 12.0 530.3 419.3
Romania 3.6 10.2 20.2 0.6 5.9 3.0 11.8 2.9 8.6 7.3 0.5 1.1 0.6 0.6 4.0 3.4 1.8 1.7 6.7 5.0 288.8 193.8
Russian
Federation
54.8 79.7 114.8 4.0 56.0 34.2 53.9 14.5 35.6 34.6 4.8 15.4 6.6 5.1 21.7 20.1 9.4 12.4 35.1 36.1 1571.3 1382.2
Slovakia 2.1 2.8 5.3 0.2 2.3 1.6 1.9 0.7 1.9 1.7 0.1 0.2 0.2 0.1 1.1 1.0 0.5 0.8 1.8 1.6 66.5 51.3
Ukraine 20.4 24.5 33.7 1.3 16.7 8.7 19.3 3.3 11.0 9.0 1.1 2.5 2.5 2.2 6.4 5.2 2.4 2.5 12.9 10.7 485.0 387.9
Northern
Europe
28.9 65.9 180.4 1.2 40.7 25.6 51.5 23.8 36.1 26.9 2.4 3.9 2.6 2.3 35.1 29.7 24.3 20.6 41.1 31.1 1286.6 1151.7
Denmark 1.7 4.0 13.2 0.1 2.2 1.3 3.8 1.8 2.2 1.8 0.1 0.2 0.2 0.1 1.8 1.7 1.5 1.0 2.4 2.0 82.6 74.1
Estonia 0.4 0.9 2.4 0.0 0.6 0.4 0.7 0.2 0.5 0.6 0.0 0.1 0.0 0.0 0.2 0.2 0.2 0.3 0.6 0.6 17.0 13.7
Finland 1.8 3.3 8.3 0.0 1.8 1.5 2.0 0.7 1.7 1.5 0.2 0.2 0.1 0.1 2.1 2.1 1.4 1.3 2.0 1.4 60.9 53.1
Iceland 0.0 0.1 0.5 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 2.9 2.4
(continued on next page)
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Table 7b (continued)
Corpus Ovary Prostate Testis Kidney Bladder Brain Thyroid Hodgkin NHL Multiple
myeloma
Leukaemia All sites
C54 C56 C61 C62 C64–66 C67 C70–72 C73 C81 C82–85,C96 C88 + C90 C91–95 C00–96/C44
F F M M M F M F M F M F M F M F M F M F M F
Ireland 1.0 2.6 5.2 0.1 1.5 0.8 1.3 0.6 1.6 1.1 0.1 0.1 0.1 0.1 1.3 1.1 0.9 0.7 1.7 1.1 44.4 39.1
Latvia 1.5 2.2 3.6 0.1 1.3 1.0 1.6 0.4 0.9 1.0 0.0 0.2 0.1 0.1 0.6 0.7 0.3 0.4 0.7 0.9 31.8 27.9
Lithuania 1.3 3.0 6.1 0.1 2.0 1.1 1.8 0.6 1.2 1.4 0.1 0.2 0.1 0.1 0.8 0.8 0.5 0.6 1.3 1.4 46.9 35.9
Norway 1.2 3.3 10.5 0.1 1.8 0.8 2.3 1.0 1.8 1.4 0.2 0.2 0.1 0.0 1.6 1.3 1.4 1.1 1.7 1.4 56.5 49.9
Sweden 2.9 6.1 24.4 0.1 3.9 2.5 4.9 2.0 3.7 2.8 0.3 0.4 0.2 0.1 3.2 2.6 2.7 2.3 4.2 3.3 114.8 105.8
United
Kingdom
17.1 40.4 106.0 0.6 25.5 16.0 33.0 16.4 22.5 15.4 1.4 2.2 1.8 1.6 23.5 19.2 15.3 12.7 26.3 18.9 828.8 749.7
Southern
Europe
45.9 78.2 202.1 2.6 59.0 29.8 116.4 30.0 59.4 48.2 4.6 7.6 6.3 4.4 50.1 41.7 30.9 31.2 76.0 57.8 2274.3 1627.1
Albania 0.5 0.3 1.8 0.1 0.7 0.4 1.2 0.4 1.7 1.2 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.8 0.7 26.5 21.0
Bosnia
Herzegovina
0.9 1.5 3.4 0.2 0.7 0.4 1.6 0.6 1.0 0.9 0.0 0.2 0.2 0.1 0.6 0.3 0.1 0.2 0.5 0.5 39.7 27.6
Croatia 1.9 3.2 7.6 0.2 2.6 1.2 2.8 0.9 2.1 2.0 0.1 0.2 0.1 0.1 1.4 1.4 0.6 0.8 1.9 1.7 77.5 55.6
Cyprus 0.2 0.4 1.0 0.0 0.1 0.1 0.4 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.1 0.4 0.3 8.4 6.3
Greece 2.8 5.8 18.2 0.3 4.0 2.0 9.2 2.0 6.2 5.4 0.3 0.4 1.2 0.9 1.4 1.1 2.0 1.9 8.4 6.3 171.1 113.7
Italy 19.6 36.2 78.1 0.8 28.0 14.0 45.5 12.0 22.6 17.4 2.3 3.6 2.6 1.6 26.1 21.6 15.7 16.2 35.3 26.5 949.9 750.4
FYR
Macedonia
1.0 0.9 2.3 0.1 0.3 0.2 1.2 0.2 1.0 0.6 0.0 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.6 0.4 27.6 18.6
Malta 0.2 0.3 0.3 0.0 0.2 0.1 0.2 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.2 0.1 4.5 3.8
Montenegro 0.2 0.3 0.7 0.0 0.2 0.1 0.3 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.2 7.8 5.7
Portugal 3.0 3.8 15.8 0.2 2.4 1.3 6.6 2.0 3.7 3.5 0.3 0.6 0.3 0.2 3.7 3.1 1.8 1.8 4.0 3.6 143.0 98.1
Serbia 3.0 5.3 13.8 0.4 3.3 1.8 5.1 1.8 5.0 4.2 0.2 0.5 0.5 0.3 2.5 2.1 1.3 1.1 4.4 3.1 149.7 108.4
Slovenia 0.7 1.5 4.2 0.1 1.1 0.6 1.4 0.6 0.9 0.6 0.1 0.1 0.1 0.0 0.8 0.8 0.5 0.5 1.0 0.8 32.7 26.0
Spain 12.1 18.8 54.8 0.4 15.3 7.6 41.0 9.1 14.7 12.0 1.0 1.9 1.2 1.0 12.7 10.7 8.5 8.3 18.3 13.8 635.8 391.8
Western
Europe
55.3 114.8 281.3 3.3 96.4 52.8 94.6 39.5 65.3 50.6 5.3 8.4 4.7 3.5 67.3 58.3 43.4 40.1 91.9 75.0 2686.1 2137.9
Austria 2.3 5.0 11.1 0.3 3.1 2.2 3.3 1.6 2.5 2.2 0.3 0.4 0.2 0.1 3.0 2.8 1.7 1.7 4.2 3.5 110.4 94.0
Belgium 3.5 7.3 19.1 0.1 4.6 2.7 7.3 2.5 3.3 2.7 0.3 0.5 0.4 0.2 3.7 3.4 2.4 2.4 5.7 4.6 173.4 124.7
France 21.5 33.9 86.1 1.0 28.9 12.9 36.5 11.2 19.4 13.5 1.6 2.3 1.8 1.3 23.1 19.7 14.2 13.5 32.0 25.2 901.1 644.6
Germany 21.3 53.8 125.5 1.5 47.1 28.3 35.4 18.6 31.0 25.6 2.6 3.9 1.6 1.3 29.6 25.3 19.8 18.0 39.8 33.8 1176.1 1000.3
Luxembourg 0.3 0.3 0.6 0.0 0.1 0.0 0.2 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.2 5.5 4.7
The
Netherlands
4.1 10.2 26.5 0.3 9.6 5.0 8.6 4.0 6.1 4.5 0.3 0.7 0.5 0.3 5.4 4.7 3.5 2.9 6.8 5.5 229.4 196.0
Switzerland 2.3 4.4 12.5 0.2 2.9 1.6 3.3 1.5 2.7 2.1 0.3 0.5 0.2 0.2 2.4 2.3 1.7 1.7 3.2 2.2 90.2 73.6
Countries for which no data were available are in italics.
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(a) Incidence − Male
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(c) Mortality − Male
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[145.2,165.4]
Fig. 3. Age-standardised rates for all cancers excluding non-melanoma skin cancers in Europe 2012.
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Fig. 4a. Age-standardised incidence rates by sex, area and country in
Europe 2012: all cancers excluding non-melanoma skin cancers.
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Fig. 4b. Age-standardised mortality rates by sex, area and country in
Europe 2012: all cancers excluding non-melanoma skin cancers.
1396 J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403mortality data from local cancer registries. The method-
ology is consistent with previous studies estimating can-
cer incidence and mortality in Europe.7,8 Short term
prediction methods have been used to prepare estimates
for 2012 from the most recently available data – specif-
ically, national mortality rates for the years 2004–2010,
and national incidence rates for 2005–2009, depending
on the availability of such data in a given country.
Although predictions are based on trends in historical
data which may or may not continue into the long-term
future, they are likely to be reasonably accurate in the
short term or when the disease rates exhibit rather stable
trends.
In addition to the incompleteness of mortality data,
there is also possible underestimation of the cancer mor-
tality in certain European countries where the number
of deaths attributed to ill-deﬁned and unknown causes
is relatively large (Table 8). Cancer mortality data are
also prone to a lower accuracy (validity) than cancer
registry statistics, mainly because of the diﬃculties in
ascertaining and certifying the cause of death. This
may have led to an underestimate of the true mortality
of cancer at speciﬁc sites. Inclusion of metastatic cancers
along with primary neoplasms for example ampliﬁes the
mortality rates for some sites such as liver, lung andbrain. This would inﬂate the national estimates of mor-
tality and possibly incidence, if the latter relies both on
the national mortality statistics and on IR/MR ratios
outside the country, as in method 2B. Therefore, some
caution must be employed in interpretation of the esti-
mated cancer mortality data. Another attempt to esti-
mate the cancer mortality in the EU-27 for 2012 using
a similar methodology was published recently.28 The
overall estimates of 1.28 million cancer deaths (717,000
in men and 566,000 in women) are very close to our esti-
mates of 1.26 million cancer deaths (707,000 in men and
555,000 in women, Table 5).
With respect to incidence, several sources of data
have been used in generating the statistics. National inci-
dence rates were provided by 24 European countries
(Table 1) representing 50% of the total European popu-
lation. For Germany and Switzerland, the projection of
incidence rates based on aggregated local cancer regis-
tries data covering a substantial part of the population
(30% and 40% respectively, method 1B) was preferred
to the “standard” M:I ratio method and the representa-
tiveness of the local registry data is of course unknown.
The resulting estimates may slightly overestimate or
underestimate the incidence rates if the increasing or
decreasing trends observed in local registries do not
2394
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Fig. 5. Age-standardised incidence and mortality rates by area and country in Europe 2012: breast cancer.
J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403 1397apply to the national population. For 12 countries, it
was necessary to estimate incidence using the predicted
national mortality in 2012 and mortality to incidence
ratios (M:I) of aggregated data from either local cancer
registries or neighbouring countries (methods 2A and
2B). This practice corrects for any discrepancy between
local and national rates of incidence, and is also robust
to deﬁciencies in the quality of mortality data, provided
these are similar nationally and locally.5 Where it is
likely that the M:I ratios will be changing rapidly,
national incidence rates have been estimated as a mean
of the most recent incidence rates obtained from local
cancer registries. This method was used for cancers of
the breast and prostate, for which screening pro-
grammes may have aﬀected the ratio between the
recorded new cases and deaths. In the absence of local
cancer registry data, M:I ratios from cancer registries
in neighbouring countries were used (method 2B). This
is evidently not ideal given the national MN and the
regional MR in Eq. (1) are not from the same vital sta-tistics systems, and the resulting incidence IN could be
distorted. Finally, the estimates for certain sites are less
accurate when one considers the mortality to incidence
ratios (M:I) with values greater than 1. This suggests
under-reporting of cancer cases by the registry (e.g. pan-
creatic cancer in elderly patients), and thus a possible
underestimate of the burden of cancer in the country.
Alternatively, M:I greater than 1 may testify ﬂawed
mortality data, if more deaths are attributed to a cancer
site because of the minimal medical information avail-
able for a patient at the time of the death certiﬁcation.
However, despite the provisos about data quality for
some sites, the general patterns of cancer in Europe
are clearly established, and with the data presented
herein, it is possible to deﬁne the priorities to cancer
control actions in Europe.
Lung cancer retains its status as the leading cause of
cancer death in Europe in 2012. The overwhelming
majority of lung cancer is caused by tobacco smoking29
and tobacco control is clearly a number one priority in
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Fig. 6a. Age-standardised incidence rates by sex, area and country in
Europe 2012: colorectal cancer.
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Fig. 6b. Age-standardised mortality rates by sex, area and country in
Europe 2012: colorectal cancer.
1398 J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403Europe, not only aimed at men, particularly the male
populations of Central and Eastern Europe, but increas-
ingly targeted towards young women. Incidence and
mortality rates in men are decreasing in many European
countries, particularly in Northern and Western areas
where the prevalence of smoking amongst men was ﬁrst
to diminish, while the lung cancer rates in Central and
Eastern Europe remain high, but are showing signs of
stabilisation or decline.30 Mortality rates in women,
who acquired the smoking habit later than men, are lar-
gely on the increase in Europe (e.g. France, Spain)
although rates are beginning to stabilise, notably in
the high-risk countries of Northern Europe.30 Primary
prevention, through eﬀorts to deter the initiation of
smoking and raise cessation rates through higher taxes,
regulations on smoking and information to the public
should have a major impact on incidence and mortality
from lung and other tobacco-related cancers, including
oral cavity and pharynx, oesophagus, pancreas, larynx
and urinary tract.31
Colorectal cancer is the second most common cause
of cancer death in both men and women (Table 4). Diets
low in fruit, vegetables and unreﬁned plant food, and
high in red meat, processed food and fat have been
shown to confer an increased risk of colorectal cancer32and there is an evidence base to suggest that mainte-
nance of a healthy diet and avoidance of a sedentary
lifestyle and obesity may reduce the risk of colorectal
cancer. The European Guidelines For Quality Assur-
ance In Colorectal Cancer Screening And Diagnosis
indicate there is good evidence that invitation to screen-
ing with FOBT using the guaiac test reduces mortality
from colorectal cancer by about 15% in average risk
populations of appropriate age, and that there is reason-
able evidence that ﬂexible sigmoidoscopy screening
reduces incidence and mortality if performed within an
organised screening programme with strict monitoring
of quality and outcomes.33 Implementation of organised
colorectal screening programmes is resource-dependent
but is underway in higher-resource countries, and
should remain a high priority as a means of early detec-
tion of the disease in Europe.
Breast cancer is the leading cancer site in women in
all countries in Europe (Table 4) and it is also the ﬁrst
cause of death from cancer in women in Europe
(Fig. 2b). It is likely that the variation observed in breast
cancer incidence across European countries (Fig. 5) may
be attributable to the variable extent and type of screen-
ing activities in operation, a diﬀerential in the prevalence
and distribution of known risk factors for breast cancer
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J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403 1399(e.g. parity, age at ﬁrst birth34), as well as possible arte-
facts in the methods of estimation. Declines in breast
cancer mortality rates in most European countries in
the 1990s were reported by several studies35,36 as a con-
sequence of the combined eﬀects of earlier detection
(part due to screening, part due to increasing aware-
ness), and a range of improvements in treatment. How-
ever, while trend analyses of mortality rates are useful in
evaluating overall success in breast cancer control, they
are of limited value in quantifying the impact of the
introduction of mammographic screening.37
Prostate cancer is the third most common cancer
diagnosed in Europe today, and it has emerged as the
most frequent cancer amongst men in Europe. General
increases in prostate cancer incidence have been
reported,38 but in most European countries, particularly
in the highest resource countries in Northern and Wes-
tern Europe, the rising trends in incidence are largely
attributable to increased detection of latent disease fol-lowing the widespread availability of PSA tests in the
late-1980s and its subsequent and rapid uptake by urol-
ogists and GPs as a screening test. Therefore the geo-
graphical variations in prostate cancer incidence rates
reported herein largely reﬂect the prevalence of PSA
testing and consequent biopsy, although other factors
such as sedentary lifestyle and obesity may be risk fac-
tors for invasive disease.39 With respect to prostate can-
cer mortality, the rates are a better proxy of risk than
incidence, revealing much less between-country varia-
tion than incidence (notably in absolute terms),
although they may be prone to variations in the quality
of reporting of the underlying cause of death.40 How-
ever, decreasing mortality trends have been observed
in several European countries after 1996 and the relative
impact of the introduction of curative treatment versus
early detection by PSA is still subject to much debate.38
Although some care should be taken when comparing
these estimates by country with those published earlier
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1400 J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403(part of the observed diﬀerences may be the result of
changes in the methodology due to extension of data
availability as for Germany and Switzerland), some
comparison at the European level with our previous esti-
mates for 20088 (3.23 million new cases of cancer and
1.72 million deaths from cancer) could be drawn. The
2012 estimates presented herein show a slight increase
in the number of new cases of cancer (in particular for
breast and prostate cancers) and a similar estimate of
the number of deaths from cancer despite the growth
and the ageing of the European population in the per-
iod. Therefore, the overall risk of getting cancer in Eur-
ope seems to be almost stabilised now although at a high
level, while the overall risk of dying from cancer in Eur-
ope is declining, with directions of change and magni-
tude varying by country and by the cancer site.35
This estimation of cancer incidence in Europe would
not be possible without population-based cancer regis-
tries functioning in many European countries. Theimportant role of registries in disease surveillance is
increasingly being recognised but should not be taken
for granted. Cancer registration in Europe is at present
facing an uncertain future as a result of funding con-
straints, inappropriate implementation of e-Health
methodology and also because of attempts to implement
legislation which would require patients to provide
informed consent to permit registration and/or opt-out
from registration.41 The latter restrictions, although
intended to safeguard patient conﬁdentiality, have led
to concerns that it would no longer be possible to mon-
itor cancer patterns and trends reliably. The inevitable
exclusion of an undetermined fraction of cases would
introduce serious biases in the data. If European govern-
ments consider the control of cancer burden an impor-
tant issue for the future of Europe, they must commit
themselves to an appropriate level of investment in can-
cer registries and legislation that would safeguard their
ability to collect population-based information.
Table 8
Percentage of ill-deﬁned causes of deaths and ill-deﬁned cancer deaths in European countries, both sexes combined, for the most recent year of
information (source World Health Organisation (WHO)) and percentage of unknown and unspeciﬁed cancer site in cancer registries included in
CI5 Vol. IX.
Country Mortality Incidence
% of ill-deﬁned causes of deaths % of unknown and ill-deﬁned cancer
deaths
% of unknown and unspeciﬁed cancer
site
Albania 11.8 0.8
Austria 2.4 2.6 1.2
Belarus 11.4 1.6
Belgium 2.6 3.9 3.1
Bulgaria 3.0 2.3 3.7
Croatia 1.1 3.5 2.3
Czech Republic 1.6 5.0 1.7
Cyprus 6.2 6.5 1.8
Denmark 4.5 5.9 3.2
Estonia 1.8 2.7 2.1
Finland 0.6 2.9 2.5
France 7.1 4.7 2.6
Germany 2.8 4.9 2.0
Greece 7.5 6.5
Hungary 0.1 2.2
Iceland 0.8 2.1 2.0
Ireland 0.3 3.7 3.4
Italy 1.6 3.8 1.5
Latvia 6.3 3.5 1.8
Lithuania 1.3 4.0 2.0
Luxembourg 2.8 1.8
Macedonia 6.5 2.0
Malta 0.9 4.2 3.7
Republic of Moldova 0.6 3.0
The Netherlands 3.9 4.0 3.9
Norway 4.9 4.2 2.7
Poland 6.5 5.5 3.4
Portugal 9.4 4.0 1.4
Romania 0.8 2.8
Russian Federation 4.6 1.2
Serbia 4.4 3.8 1.4
Slovakia 1.4 2.8 1.0
Slovenia 1.3 2.9 0.9
Spain 2.9 4.8 3.1
Sweden 3.6 3.5 3.0
Switzerland 2.9 1.6
United Kingdom 1.8 6.9 4.2
Ukraine 3.1
Europe 3.8 4.6 2.8
Countries for which data were available according ICD-10 Mortality Tabulation List 1 only are in italics.
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